BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat Rev Immunol 2015;15:405-14. [PMID: 26027717 DOI: 10.1038/nri3845] [Cited by in Crossref: 509] [Cited by in F6Publishing: 586] [Article Influence: 72.7] [Reference Citation Analysis]
Number Citing Articles
1 Dong X, Pan P, Ye J, Zhang Q, Zhang X. Hybrid M13 bacteriophage-based vaccine platform for personalized cancer immunotherapy. Biomaterials 2022;289:121763. [DOI: 10.1016/j.biomaterials.2022.121763] [Reference Citation Analysis]
2 Liu Y, Bai X, Lyu C, Fang J, Zhang F, Wu WH, Wei W, Zhang WB. Mechano-bioconjugation Strategy Empowering Fusion Protein Therapeutics with Aggregation Resistance, Prolonged Circulation, and Enhanced Antitumor Efficacy. J Am Chem Soc 2022. [PMID: 36178288 DOI: 10.1021/jacs.2c06532] [Reference Citation Analysis]
3 Marmonti E, Oliva-ramirez J, Haymaker C. Dendritic Cells: The Long and Evolving Road towards Successful Targetability in Cancer. Cells 2022;11:3028. [DOI: 10.3390/cells11193028] [Reference Citation Analysis]
4 Zhou X, Santos GS, Zhan Y, Oliveira MMS, Rezaei S, Singh M, Peuget S, Westerberg LS, Johnsen JI, Selivanova G. Mutant p53 gain of function mediates cancer immune escape that is counteracted by APR-246. Br J Cancer 2022. [PMID: 36138076 DOI: 10.1038/s41416-022-01971-8] [Reference Citation Analysis]
5 Zhao J, Tang Z, Selvaraju M, Johnson KA, Douglas JT, Gao PF, Petrassi HM, Wang MZ, Wang J. Cellular Target Deconvolution of Small Molecules Using a Selection-Based Genetic Screening Platform. ACS Cent Sci . [DOI: 10.1021/acscentsci.2c00609] [Reference Citation Analysis]
6 Honma Y, Shibata M, Morino K, Koya Y, Hayashi T, Ogino N, Kusanaga M, Oe S, Miyagawa K, Abe S, Tabaru A, Harada M. Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C. Dig Dis Sci. [DOI: 10.1007/s10620-022-07686-3] [Reference Citation Analysis]
7 Huang L, Liu Z, Wu C, Lin J, Liu N. Magnetic nanoparticles enhance the cellular immune response of dendritic cell tumor vaccines by realizing the cytoplasmic delivery of tumor antigens. Bioengineering & Transla Med. [DOI: 10.1002/btm2.10400] [Reference Citation Analysis]
8 Simoes DCM, Paschalidis N, Kourepini E, Panoutsakopoulou V. An integrin axis induces IFN-β production in plasmacytoid dendritic cells. J Cell Biol 2022;221:e202102055. [PMID: 35878016 DOI: 10.1083/jcb.202102055] [Reference Citation Analysis]
9 Yang Z, Sun JK, Lee MM, Chan MK. Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy. J Immunother Cancer 2022;10:e005068. [PMID: 36104100 DOI: 10.1136/jitc-2022-005068] [Reference Citation Analysis]
10 Musella M, Guarracino A, Manduca N, Galassi C, Ruggiero E, Potenza A, Maccafeo E, Manic G, Mattiello L, Soliman Abdel Rehim S, Signore M, Pietrosanto M, Helmer-Citterich M, Pallocca M, Fanciulli M, Bruno T, De Nicola F, Corleone G, Di Benedetto A, Ercolani C, Pescarmona E, Pizzuti L, Guidi F, Sperati F, Vitale S, Macchia D, Spada M, Schiavoni G, Mattei F, De Ninno A, Businaro L, Lucarini V, Bracci L, Aricò E, Ziccheddu G, Facchiano F, Rossi S, Sanchez M, Boe A, Biffoni M, De Maria R, Vitale I, Sistigu A. Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B. Nat Immunol 2022. [PMID: 36002648 DOI: 10.1038/s41590-022-01290-3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
11 Liu G, Qiu Y, Zhang P, Chen Z, Chen S, Huang W, Wang B, Yu X, Guo D. Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies. Pharmaceutics 2022;14:1762. [DOI: 10.3390/pharmaceutics14091762] [Reference Citation Analysis]
12 Li Z, Chu Z, Yang J, Qian H, Xu J, Chen B, Tian T, Chen H, Xu Y, Wang F. Immunogenic Cell Death Augmented by Manganese Zinc Sulfide Nanoparticles for Metastatic Melanoma Immunotherapy. ACS Nano 2022. [PMID: 35981098 DOI: 10.1021/acsnano.2c08013] [Reference Citation Analysis]
13 Xiao L, Huang Y, Li Q, Wang S, Ma L, Fan Z, Tang Z, Yuan X, Liu B. Identification of a prognostic classifier based on EMT-related lncRNAs and the function of LINC01138 in tumor progression for lung adenocarcinoma. Front Mol Biosci 2022;9:976878. [DOI: 10.3389/fmolb.2022.976878] [Reference Citation Analysis]
14 Xue B, Li H, Liu S, Feng Q, Xu Y, Deng R, Chen S, Wang J, Li X, Wan M, Tang S, Zhu H. The redox cycling of STAT2 maintains innate immune homeostasis. Cell Rep 2022;40:111215. [PMID: 35977519 DOI: 10.1016/j.celrep.2022.111215] [Reference Citation Analysis]
15 Johnstone M, Vinaixa D, Turi M, Morelli E, Anderson KC, Gulla A. Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma. Cells 2022;11:2519. [PMID: 36010596 DOI: 10.3390/cells11162519] [Reference Citation Analysis]
16 Wang D, Peng H, Hu Y, Piao X, Gao D, Sha Y. Distinctive gene expression patterns in pregnancy-associated breast cancer. Front Genet 2022;13:850195. [DOI: 10.3389/fgene.2022.850195] [Reference Citation Analysis]
17 Wu Z, Lin Y, Liu L, Hou Y, Qin W, Zhang L, Jiang S, Yang Q, Bai Y, Shi L. Identification of Cytosolic DNA Sensor cGAS-STING as Immune-Related Risk Factor in Renal Carcinoma following Pan-Cancer Analysis. Journal of Immunology Research 2022;2022:1-11. [DOI: 10.1155/2022/7978042] [Reference Citation Analysis]
18 Li K, Gong Y, Qiu D, Tang H, Zhang J, Yuan Z, Huang Y, Qin Y, Ye L, Yang Y. Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. J Immunother Cancer 2022;10:e004006. [PMID: 36002188 DOI: 10.1136/jitc-2021-004006] [Reference Citation Analysis]
19 Zhang Z, Liu X, Chen D, Yu J. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther 2022;7:258. [PMID: 35906199 DOI: 10.1038/s41392-022-01102-y] [Reference Citation Analysis]
20 Sun J, Li L, Chen H, Gan L, Guo X, Sun J. Identification and Validation of an m7G-Related lncRNAs Signature for Prognostic Prediction and Immune Function Analysis in Endometrial Cancer. Genes 2022;13:1301. [DOI: 10.3390/genes13081301] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Tai J, Kwak J, Han M, Kim TH. Different Roles of Dendritic Cells for Chronic Rhinosinusitis Treatment According to Phenotype. IJMS 2022;23:8032. [DOI: 10.3390/ijms23148032] [Reference Citation Analysis]
22 Mekers VE, Kho VM, Ansems M, Adema GJ. cGAS/cGAMP/STING signal propagation in the tumor microenvironment: key role for myeloid cells in antitumor immunity. Radiother Oncol 2022:S0167-8140(22)04210-4. [PMID: 35870728 DOI: 10.1016/j.radonc.2022.07.014] [Reference Citation Analysis]
23 Aristin Revilla S, Kranenburg O, Coffer PJ. Colorectal Cancer-Infiltrating Regulatory T Cells: Functional Heterogeneity, Metabolic Adaptation, and Therapeutic Targeting. Front Immunol 2022;13:903564. [DOI: 10.3389/fimmu.2022.903564] [Reference Citation Analysis]
24 Budczies J, Kluck K, Beck S, Ourailidis I, Allgäuer M, Menzel M, Kazdal D, Perkhofer L, Kleger A, Schirmacher P, Seufferlein T, Stenzinger A. Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types. J Pathol Clin Res 2022;8:371-82. [PMID: 35384413 DOI: 10.1002/cjp2.271] [Reference Citation Analysis]
25 Zhang H, Yu P, Tomar VS, Chen X, Atherton MJ, Lu Z, Zhang HG, Li S, Ortiz A, Gui J, Leu NA, Yan F, Blanco A, Meyer-Ficca ML, Meyer RG, Beiting DP, Li J, Nunez-Cruz S, O'Connor RS, Johnson LR, Minn AJ, George SS, Koumenis C, Diehl JA, Milone MC, Zheng H, Fuchs SY. Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nat Cancer 2022;3:808-20. [PMID: 35637402 DOI: 10.1038/s43018-022-00383-0] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
26 Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V. PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors. Oncoimmunology 2022;11:2083755. [PMID: 35756843 DOI: 10.1080/2162402X.2022.2083755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Gupta SL, Basu S, Soni V, Jaiswal RK. Immunotherapy: an alternative promising therapeutic approach against cancers. Mol Biol Rep 2022. [PMID: 35759082 DOI: 10.1007/s11033-022-07525-8] [Reference Citation Analysis]
28 Hussain T, Domnich M, Bordbari S, Pylaeva E, Siakaeva E, Spyra I, Ozel I, Droege F, Squire A, Lienenklaus S, Sutter K, Hasenberg A, Gunzer M, Lang S, Jablonska J. IFNAR1 Deficiency Impairs Immunostimulatory Properties of Neutrophils in Tumor-Draining Lymph Nodes. Front Immunol 2022;13:878959. [DOI: 10.3389/fimmu.2022.878959] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Austin E, Huang A, Wang JY, Cohen M, Heilman E, Maverakis E, Michl J, Jagdeo J. Red Light Phototherapy Using Light-Emitting Diodes Inhibits Melanoma Proliferation and Alters Tumor Microenvironments. Front Oncol 2022;12:928484. [DOI: 10.3389/fonc.2022.928484] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Perego M, Fu S, Cao Y, Kossenkov A, Yao M, Alicea-Torres K, Liu W, Jiang Z, Chen Z, Fuchs SY, Zhou J, Gabrilovich DI. Mechanisms regulating transitory suppressive activity of neutrophils in newborns: PMNs-MDSCs in newborns. J Leukoc Biol 2022. [PMID: 35726818 DOI: 10.1002/JLB.4HI0921-514RR] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Yim S, Hwang W, Han N, Lee D. Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens. Front Immunol 2022;13:884561. [PMID: 35651625 DOI: 10.3389/fimmu.2022.884561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Li Q, Oduro PK, Guo R, Li R, Leng L, Kong X, Wang Q, Yang L. Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors. Front Cell Infect Microbiol 2022;12:921534. [DOI: 10.3389/fcimb.2022.921534] [Reference Citation Analysis]
33 Shang Q, Dong Y, Su Y, Leslie F, Sun M, Wang F. Local scaffold-assisted delivery of immunotherapeutic agents for improved cancer immunotherapy. Adv Drug Deliv Rev 2022;185:114308. [PMID: 35472398 DOI: 10.1016/j.addr.2022.114308] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Tomita Y, Goto Y, Sakata S, Imamura K, Minemura A, Oka K, Hayashi A, Jodai T, Akaike K, Anai M, Hamada S, Iyama S, Saruwatari K, Saeki S, Takahashi M, Ikeda T, Sakagami T. Clostridium butyricum therapy restores the decreased efficacy of immune checkpoint blockade in lung cancer patients receiving proton pump inhibitors. OncoImmunology 2022;11:2081010. [DOI: 10.1080/2162402x.2022.2081010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Ramos RN, Tosch C, Kotsias F, Claudepierre MC, Schmitt D, Remy-Ziller C, Hoffmann C, Ricordel M, Nourtier V, Farine I, Laruelle L, Hortelano J, Spring-Giusti C, Sedlik C, Le Tourneau C, Hoffmann C, Silvestre N, Erbs P, Bendjama K, Thioudellet C, Quemeneur E, Piaggio E, Rittner K. Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination. Clin Transl Immunology 2022;11:e1392. [PMID: 35573979 DOI: 10.1002/cti2.1392] [Reference Citation Analysis]
36 Sosa Cuevas E, Bendriss-Vermare N, Mouret S, De Fraipont F, Charles J, Valladeau-Guilemond J, Chaperot L, Aspord C. Diversification of circulating and tumor-infiltrating plasmacytoid DCs towards the P3 (CD80+ PDL1-)-pDC subset negatively correlated with clinical outcomes in melanoma patients. Clin Transl Immunology 2022;11:e1382. [PMID: 35517992 DOI: 10.1002/cti2.1382] [Reference Citation Analysis]
37 Zhang LX, Gao J, Long X, Zhang PF, Yang X, Zhu SQ, Pei X, Qiu BQ, Chen SW, Lu F, Lin K, Xu JJ, Wu YB. The circular RNA circHMGB2 drives immunosuppression and anti-PD-1 resistance in lung adenocarcinomas and squamous cell carcinomas via the miR-181a-5p/CARM1 axis. Mol Cancer 2022;21:110. [PMID: 35525959 DOI: 10.1186/s12943-022-01586-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
38 Chen Z, He L, Zhao L, Zhang G, Wang Z, Zhu P, Liu B. circREEP3 Drives Colorectal Cancer Progression via Activation of FKBP10 Transcription and Restriction of Antitumor Immunity. Adv Sci (Weinh) 2022;9:e2105160. [PMID: 35233964 DOI: 10.1002/advs.202105160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
39 Tseng SH, Cheng MA, Farmer E, Ferrall L, Kung YJ, Lam B, Lim L, Wu TC, Hung CF. Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity. J Immunother Cancer 2022;10:e004342. [PMID: 35459734 DOI: 10.1136/jitc-2021-004342] [Reference Citation Analysis]
40 Iwamoto A, Tsukamoto H, Nakayama H, Oshiumi H. E3 Ubiquitin Ligase Riplet Is Expressed in T Cells and Suppresses T Cell-Mediated Antitumor Immune Responses. J Immunol 2022;208:2067-76. [PMID: 35365564 DOI: 10.4049/jimmunol.2100096] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Seneff S, Nigh G, Kyriakopoulos AM, McCullough PA. Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs. Food Chem Toxicol 2022;164:113008. [PMID: 35436552 DOI: 10.1016/j.fct.2022.113008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
42 Shinchi H, Komaki F, Yuki M, Ohara H, Hayakawa N, Wakao M, Cottam HB, Hayashi T, Carson DA, Moroishi T, Suda Y. Glyco-Nanoadjuvants: Impact of Linker Length for Conjugating a Synthetic Small-Molecule TLR7 Ligand to Glyco-Nanoparticles on Immunostimulatory Effects. ACS Chem Biol 2022;17:957-68. [PMID: 35353497 DOI: 10.1021/acschembio.2c00108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Li J, Meng Q, Zhou X, Zhao H, Wang K, Niu H, Wang Y. Gospel of malignant Glioma: Oncolytic virus therapy. Gene 2022;818:146217. [PMID: 35093451 DOI: 10.1016/j.gene.2022.146217] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
44 Dai W, Zhang J, Li S, He F, Liu Q, Gong J, Yang Z, Gong Y, Tang F, Wang Z, Xie C. Protein Arginine Methylation: An Emerging Modification in Cancer Immunity and Immunotherapy. Front Immunol 2022;13:865964. [DOI: 10.3389/fimmu.2022.865964] [Reference Citation Analysis]
45 Yang R, Yu S, Xu T, Zhang J, Wu S. Emerging role of RNA sensors in tumor microenvironment and immunotherapy. J Hematol Oncol 2022;15:43. [PMID: 35413927 DOI: 10.1186/s13045-022-01261-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Jin S, Li M, Chang H, Wang R, Zhang Z, Zhang J, He Y, Ma H. The m6A demethylase ALKBH5 promotes tumor progression by inhibiting RIG-I expression and interferon alpha production through the IKKε/TBK1/IRF3 pathway in head and neck squamous cell carcinoma. Mol Cancer 2022;21:97. [PMID: 35395767 DOI: 10.1186/s12943-022-01572-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
47 Daniel S, Kis Z, Kontoravdi C, Shah N. Quality by Design for enabling RNA platform production processes. Trends in Biotechnology 2022. [DOI: 10.1016/j.tibtech.2022.03.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Huang J, Chen S, Lin C. Targeting Cancer Stem Cells through Epigenetic Modulation of Interferon Response. JPM 2022;12:556. [DOI: 10.3390/jpm12040556] [Reference Citation Analysis]
49 Maiorano BA, Lorusso D, Maiorano MFP, Ciardiello D, Parrella P, Petracca A, Cormio G, Maiello E. The Interplay between PARP Inhibitors and Immunotherapy in Ovarian Cancer: The Rationale behind a New Combination Therapy. Int J Mol Sci 2022;23:3871. [PMID: 35409229 DOI: 10.3390/ijms23073871] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
50 Beiss V, Mao C, Fiering SN, Steinmetz NF. Cowpea Mosaic Virus Outperforms Other Members of the Secoviridae as In Situ Vaccine for Cancer Immunotherapy. Mol Pharm 2022. [PMID: 35333531 DOI: 10.1021/acs.molpharmaceut.2c00058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Stickdorn J, Stein L, Arnold-Schild D, Hahlbrock J, Medina-Montano C, Bartneck J, Ziß T, Montermann E, Kappel C, Hobernik D, Haist M, Yurugi H, Raabe M, Best A, Rajalingam K, Radsak MP, David SA, Koynov K, Bros M, Grabbe S, Schild H, Nuhn L. Systemically Administered TLR7/8 Agonist and Antigen-Conjugated Nanogels Govern Immune Responses against Tumors. ACS Nano 2022;16:4426-43. [PMID: 35103463 DOI: 10.1021/acsnano.1c10709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
52 Hamon P, Gerbé De Thoré M, Classe M, Signolle N, Liu W, Bawa O, Meziani L, Clémenson C, Milliat F, Deutsch E, Mondini M. TGFβ receptor inhibition unleashes interferon-β production by tumor-associated macrophages and enhances radiotherapy efficacy. J Immunother Cancer 2022;10:e003519. [PMID: 35301235 DOI: 10.1136/jitc-2021-003519] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Chen L, Zhou C, Chen Q, Shang J, Liu Z, Guo Y, Li C, Wang H, Ye Q, Li X, Zu S, Li F, Xia Q, Zhou T, Li A, Wang C, Chen Y, Wu A, Qin C, Man J. Oncolytic Zika virus promotes intratumoral T cell infiltration and improves immunotherapy efficacy in glioblastoma. Mol Ther Oncolytics 2022;24:522-34. [PMID: 35229030 DOI: 10.1016/j.omto.2022.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Goad DW, Bressy C, Holbrook MC, Grdzelishvili VZ. Acquired chemoresistance can lead to increased resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus. Mol Ther Oncolytics 2022;24:59-76. [PMID: 34977342 DOI: 10.1016/j.omto.2021.11.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Yu R, Zhu B, Chen D. Type I interferon-mediated tumor immunity and its role in immunotherapy. Cell Mol Life Sci 2022;79:191. [PMID: 35292881 DOI: 10.1007/s00018-022-04219-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
56 Song H, Su Q, Shi W, Huang P, Zhang C, Zhang C, Liu Q, Wang W. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy. Acta Biomater 2022;141:398-407. [PMID: 35007785 DOI: 10.1016/j.actbio.2022.01.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
57 Carson CS, Becker KW, Garland KM, Pagendarm HM, Stone PT, Arora K, Wang-Bishop L, Baljon JJ, Cruz LD, Joyce S, Wilson JT. A nanovaccine for enhancing cellular immunity via cytosolic Co-delivery of antigen and PolyIC RNA. J Control Release 2022:S0168-3659(22)00146-8. [PMID: 35301055 DOI: 10.1016/j.jconrel.2022.03.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
58 Cattolico C, Bailey P, Barry ST. Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC. Front Cell Dev Biol 2022;10:816517. [PMID: 35273962 DOI: 10.3389/fcell.2022.816517] [Reference Citation Analysis]
59 Zhao S, Xu B, Ma W, Chen H, Jiang C, Cai J, Meng X. DNA Damage Repair in Brain Tumor Immunotherapy. Front Immunol 2021;12:829268. [PMID: 35095931 DOI: 10.3389/fimmu.2021.829268] [Reference Citation Analysis]
60 Wang H, Zhang D, Cui X, Dai Y, Wang C, Feng W, Lv X, Li Y, Wang L, Ru Y, Zhang Y, Ren Q, Zheng G. Loss of IRF7 accelerates acute myeloid leukemia progression and induces VCAM1-VLA-4 mediated intracerebral invasion. Oncogene. [DOI: 10.1038/s41388-022-02233-w] [Reference Citation Analysis]
61 Bao P, Zheng Z, Ye J, Zhang X. Apoptotic Body-Mediated Intracellular Delivery Strategy for Enhanced STING Activation and Improved Tumor Immunogenicity. Nano Lett . [DOI: 10.1021/acs.nanolett.1c03996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
62 Li M, Xu J, Jiang C, Zhang J, Sun T. Predictive and Prognostic Role of Peripheral Blood T-Cell Subsets in Triple-Negative Breast Cancer. Front Oncol 2022;12:842705. [PMID: 35242718 DOI: 10.3389/fonc.2022.842705] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
63 Andersen JK, Miletic H, Hossain JA. Tumor-Associated Macrophages in Gliomas—Basic Insights and Treatment Opportunities. Cancers 2022;14:1319. [DOI: 10.3390/cancers14051319] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
64 Plundrich D, Chikhladze S, Fichtner-Feigl S, Feuerstein R, Briquez PS. Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer. Int J Mol Sci 2022;23:2782. [PMID: 35269922 DOI: 10.3390/ijms23052782] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
65 Luo X, Ji X, Xie M, Zhang T, Wang Y, Sun M, Huang W, Xia L. Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy. Cancers (Basel) 2022;14:1165. [PMID: 35267473 DOI: 10.3390/cancers14051165] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
66 Ghosh JC, Perego M, Agarwal E, Bertolini I, Wang Y, Goldman AR, Tang HY, Kossenkov AV, Libby CJ, Languino LR, Plow EF, Morotti A, Ottobrini L, Locatelli M, Speicher DW, Caino MC, Cassel J, Salvino JM, Robert ME, Vaira V, Altieri DC. Ghost mitochondria drive metastasis through adaptive GCN2/Akt therapeutic vulnerability. Proc Natl Acad Sci U S A 2022;119:e2115624119. [PMID: 35177476 DOI: 10.1073/pnas.2115624119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
67 Arnaiz E, Harris AL. Role of Hypoxia in the Interferon Response. Front Immunol 2022;13:821816. [DOI: 10.3389/fimmu.2022.821816] [Reference Citation Analysis]
68 Sharma BR, Karki R, Sundaram B, Wang Y, Vogel P, Kanneganti T. The Transcription Factor IRF9 Promotes Colorectal Cancer via Modulating the IL-6/STAT3 Signaling Axis. Cancers 2022;14:919. [DOI: 10.3390/cancers14040919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Zhang T, Wang Y, Li Q, Lin L, Xu C, Xue Y, Hu M, Shi Y, Wang Y. Mesenchymal stromal cells equipped by IFNα empower T cells with potent anti-tumor immunity. Oncogene 2022. [PMID: 35145233 DOI: 10.1038/s41388-022-02201-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Kroemer G, Galassi C, Zitvogel L, Galluzzi L. Immunogenic cell stress and death. Nat Immunol 2022. [PMID: 35145297 DOI: 10.1038/s41590-022-01132-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 41.0] [Reference Citation Analysis]
71 Wang D, Zhao H, Shen Y, Chen Q. A Variety of Nucleic Acid Species Are Sensed by cGAS, Implications for Its Diverse Functions. Front Immunol 2022;13:826880. [DOI: 10.3389/fimmu.2022.826880] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Rubin JB. The spectrum of sex differences in cancer. Trends in Cancer 2022. [DOI: 10.1016/j.trecan.2022.01.013] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
73 Zheng C, Zhang W, Wang J, Zhai Y, Xiong F, Cai Y, Gong X, Zhu B, Zhu HH, Wang H, Li Y, Zhang P. Lenvatinib- and vadimezan-loaded synthetic high-density lipoprotein for combinational immunochemotherapy of metastatic triple-negative breast cancer. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.021] [Reference Citation Analysis]
74 Zeng Y, Li S, Zhang S, Wang L, Yuan H, Hu F. Cell membrane coated-nanoparticles for cancer immunotherapy. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.02.023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
75 Meier SL, Satpathy AT, Wells DK. Bystander T cells in cancer immunology and therapy. Nat Cancer 2022;3:143-55. [PMID: 35228747 DOI: 10.1038/s43018-022-00335-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Atukorale PU, Moon TJ, Bokatch AR, Lusi CF, Routhier JT, Deng VJ, Karathanasis E. Dual agonist immunostimulatory nanoparticles combine with PD1 blockade for curative neoadjuvant immunotherapy of aggressive cancers. Nanoscale 2022;14:1144-59. [PMID: 35023530 DOI: 10.1039/d1nr06577g] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Huang Y, Huang J, Tseng L, Yu P, Chen S, Lin C. High Expression of Interferon Pathway Genes CXCL10 and STAT2 Is Associated with Activated T-Cell Signature and Better Outcome of Oral Cancer Patients. JPM 2022;12:140. [DOI: 10.3390/jpm12020140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Wang S, Bai J. Functions and roles of IFIX, a member of the human HIN-200 family, in human diseases. Mol Cell Biochem 2022. [PMID: 35039991 DOI: 10.1007/s11010-021-04297-w] [Reference Citation Analysis]
79 Xie P, Wu S, Guo L, Ren J, Cai K, Zhou M, Liu W, Yang S. Identification of Candidate Target Genes and Immune Cells in Oral Squamous Cell Carcinoma. Comput Math Methods Med 2021;2021:5802110. [PMID: 35003322 DOI: 10.1155/2021/5802110] [Reference Citation Analysis]
80 Ugalde-Morales E, Grassmann F, Humphreys K, Li J, Eriksson M, Tobin NP, Lindström LS, Vallon-Christersson J, Borg Å, Hall P, Czene K. Interval breast cancer is associated with interferon immune response. Eur J Cancer 2022;162:194-205. [PMID: 35026490 DOI: 10.1016/j.ejca.2021.12.003] [Reference Citation Analysis]
81 Guo E, Xiao R, Wu Y, Lu F, Liu C, Yang B, Li X, Fu Y, Wang Z, Li Y, Huang Y, Li F, Wu X, You L, Qin T, Lu Y, Huang X, Ma D, Mills GB, Sun C, Chen G. WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. J Exp Med 2022;219:e20210789. [PMID: 34825915 DOI: 10.1084/jem.20210789] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
82 Fu X, De Angelis C, Schiff R. Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic. Endocrinology 2022;163:bqab235. [PMID: 34791151 DOI: 10.1210/endocr/bqab235] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
83 Li K, Yuan D, Chen W, Ma R, Xian Y. (S)-(-)-N-[2-(3-Hydroxy-2-oxo-2,3-dihydro-1H-indol-3-yl)-ethyl]-acetamide inhibits colon cancer growth via the STAT1 pathway. Food Sci Technol 2022;42:e49121. [DOI: 10.1590/fst.49121] [Reference Citation Analysis]
84 Someya M, Fukushima Y, Hasegawa T, Tsuchiya T, Kitagawa M, Gocho T, Mafune S, Ikeuchi Y, Kozuka Y, Hirohashi Y, Torigoe T, Iwasaki M, Matsuura M, Saito T, Sakata KI. Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy. Jpn J Radiol 2022. [PMID: 34973113 DOI: 10.1007/s11604-021-01231-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Prasad HSN, Ananda A, Lohith T, Prabhuprasad P, Jayanth H, Krishnamurthy N, Sridhar M, Mallesha L, Mallu P. Design, synthesis, molecular docking and DFT computational insight on the structure of Piperazine sulfynol derivatives as a new antibacterial contender against superbugs MRSA. Journal of Molecular Structure 2022;1247:131333. [DOI: 10.1016/j.molstruc.2021.131333] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
86 Ka NL, Lim GY, Hwang S, Kim SS, Lee MO. IFI16 inhibits DNA repair that potentiates type-I interferon-induced antitumor effects in triple negative breast cancer. Cell Rep 2021;37:110138. [PMID: 34936865 DOI: 10.1016/j.celrep.2021.110138] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
87 Arnaiz E, Miar A, Dias Junior AG, Prasad N, Schulze U, Waithe D, Nathan JA, Rehwinkel J, Harris AL. Hypoxia Regulates Endogenous Double-Stranded RNA Production via Reduced Mitochondrial DNA Transcription. Front Oncol 2021;11:779739. [PMID: 34900733 DOI: 10.3389/fonc.2021.779739] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
88 García-Estevez L, González-Martínez S, Moreno-Bueno G. The Leptin Axis and Its Association With the Adaptive Immune System in Breast Cancer. Front Immunol 2021;12:784823. [PMID: 34868066 DOI: 10.3389/fimmu.2021.784823] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Zhou D, Jiang K, Hong R, Lu Q, Xia W, Li M, Zheng C, Zheng Q, Xu F, Wang S. Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer. Front Oncol 2021;11:747012. [PMID: 34858823 DOI: 10.3389/fonc.2021.747012] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
90 Zheng X, Liu Z, Mi M, Wen Q, Wu G, Zhang L. Disulfiram Improves the Anti-PD-1 Therapy Efficacy by Regulating PD-L1 Expression via Epigenetically Reactivation of IRF7 in Triple Negative Breast Cancer. Front Oncol 2021;11:734853. [PMID: 34858816 DOI: 10.3389/fonc.2021.734853] [Reference Citation Analysis]
91 Aiba T, Hattori C, Sugisaka J, Shimizu H, Ono H, Domeki Y, Saito R, Kawana S, Kawashima Y, Terayama K, Toi Y, Nakamura A, Yamanda S, Kimura Y, Suzuki Y, Niida A, Sugawara S. Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers. PLoS One 2021;16:e0260500. [PMID: 34843570 DOI: 10.1371/journal.pone.0260500] [Reference Citation Analysis]
92 Lv J, Shi Q, Han Y, Li W, Liu H, Zhang J, Niu C, Gao G, Fu Y, Zhi R, Wu K, Li S, Gu F, Fu L. Spatial transcriptomics reveals gene expression characteristics in invasive micropapillary carcinoma of the breast. Cell Death Dis 2021;12:1095. [PMID: 34799559 DOI: 10.1038/s41419-021-04380-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
93 Duong E, Fessenden TB, Lutz E, Dinter T, Yim L, Blatt S, Bhutkar A, Wittrup KD, Spranger S. Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity 2021:S1074-7613(21)00458-1. [PMID: 34800368 DOI: 10.1016/j.immuni.2021.10.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 30.0] [Reference Citation Analysis]
94 Shi LZ, Bonner JA. Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis. Int J Mol Sci 2021;22:12295. [PMID: 34830176 DOI: 10.3390/ijms222212295] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
95 Nakazawa Y, Nishiyama N, Koizumi H, Kanemaru K, Nakahashi-Oda C, Shibuya A. Tumor-derived extracellular vesicles regulate tumor-infiltrating regulatory T cells via the inhibitory immunoreceptor CD300a. Elife 2021;10:e61999. [PMID: 34751648 DOI: 10.7554/eLife.61999] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
96 Fan L, Xu G, Cao J, Li M, Zhang H, Li F, Qi X, Zhang X, Li Z, Han P, Yang X. Type I Interferon Promotes Antitumor T Cell Response in CRPC by Regulating MDSC. Cancers (Basel) 2021;13:5574. [PMID: 34771735 DOI: 10.3390/cancers13215574] [Reference Citation Analysis]
97 Zhou B, Lawrence T, Liang Y. The Role of Plasmacytoid Dendritic Cells in Cancers. Front Immunol 2021;12:749190. [PMID: 34737750 DOI: 10.3389/fimmu.2021.749190] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
98 Zhu S, Ma AH, Zhu Z, Adib E, Rao T, Li N, Ni K, Chittepu VCSR, Prabhala R, Garisto Risco J, Kwiatkowski D, Mouw K, Sonpavde G, Cheng F, Pan CX. Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer. J Immunother Cancer 2021;9:e002917. [PMID: 34725212 DOI: 10.1136/jitc-2021-002917] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
99 Wu G, Yang Y, Zhu Y, Li Y, Zhai Z, An L, Liu M, Zheng Y, Wang Y, Zhou Y, Guo Q. Comprehensive Analysis to Identify the Epithelial-Mesenchymal Transition-Related Immune Signatures as a Prognostic and Therapeutic Biomarkers in Hepatocellular Carcinoma. Front Surg 2021;8:742443. [PMID: 34722623 DOI: 10.3389/fsurg.2021.742443] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
100 Xie B, Liang X, Yue W, Ma J, Li X, Zhang N, Wang P, Liu C, Shi X, Qiao J, Zou P, Li M. Targeting cytokinesis bridge proteins to kill high-CIN type tumors. Fundamental Research 2021;1:752-66. [DOI: 10.1016/j.fmre.2021.08.015] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
101 Kuiken HJ, Dhakal S, Selfors LM, Friend CM, Zhang T, Callari M, Schackmann RCJ, Gray GK, Crowdis J, Bhang HC, Baslan T, Stegmeier F, Gygi SP, Caldas C, Brugge JS. Clonal populations of a human TNBC model display significant functional heterogeneity and divergent growth dynamics in distinct contexts. Oncogene 2021. [PMID: 34703030 DOI: 10.1038/s41388-021-02075-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Zeng J, Li X, Sander M, Zhang H, Yan G, Lin Y. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas. Front Immunol 2021;12:721830. [PMID: 34675919 DOI: 10.3389/fimmu.2021.721830] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
103 Zhou D, Wu Y, Jiang K, Xu F, Hong R, Wang S. Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients. Genomics 2021;113:4088-97. [PMID: 34666190 DOI: 10.1016/j.ygeno.2021.10.010] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
104 Gerard CL, Delyon J, Wicky A, Homicsko K, Cuendet MA, Michielin O. Turning tumors from cold to inflamed to improve immunotherapy response. Cancer Treat Rev 2021;101:102227. [PMID: 34656019 DOI: 10.1016/j.ctrv.2021.102227] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
105 Ding J, Sui D, Liu M, Su Y, Wang Y, Liu M, Luo X, Liu X, Deng Y, Song Y. Sialic acid conjugate-modified liposomes enable tumor homing of epirubicin via neutrophil/monocyte infiltration for tumor therapy. Acta Biomater 2021;134:702-15. [PMID: 34339869 DOI: 10.1016/j.actbio.2021.07.063] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
106 Andersson A, Larsson L, Stenbeck L, Salmén F, Ehinger A, Wu SZ, Al-Eryani G, Roden D, Swarbrick A, Borg Å, Frisén J, Engblom C, Lundeberg J. Spatial deconvolution of HER2-positive breast cancer delineates tumor-associated cell type interactions. Nat Commun 2021;12:6012. [PMID: 34650042 DOI: 10.1038/s41467-021-26271-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
107 Lam KC, Araya RE, Huang A, Chen Q, Di Modica M, Rodrigues RR, Lopès A, Johnson SB, Schwarz B, Bohrnsen E, Cogdill AP, Bosio CM, Wargo JA, Lee MP, Goldszmid RS. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell 2021;184:5338-5356.e21. [PMID: 34624222 DOI: 10.1016/j.cell.2021.09.019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 50] [Article Influence: 2.0] [Reference Citation Analysis]
108 Bronger H. Immunology and Immune Checkpoint Inhibition in Ovarian Cancer - Current Aspects. Geburtshilfe Frauenheilkd 2021;81:1128-44. [PMID: 34629492 DOI: 10.1055/a-1475-4335] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
109 Hull R, Lolas G, Makrogkikas S, Jensen LD, Syrigos KN, Evangelou G, Padayachy L, Egbor C, Mehrotra R, Makhafola TJ, Oyomno M, Dlamini Z. Microbiomics in Collusion with the Nervous System in Carcinogenesis: Diagnosis, Pathogenesis and Treatment. Microorganisms 2021;9:2129. [PMID: 34683450 DOI: 10.3390/microorganisms9102129] [Reference Citation Analysis]
110 Sun L, Kees T, Almeida AS, Liu B, He XY, Ng D, Han X, Spector DL, McNeish IA, Gimotty P, Adams S, Egeblad M. Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell 2021;39:1361-1374.e9. [PMID: 34478639 DOI: 10.1016/j.ccell.2021.08.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 21] [Article Influence: 1.0] [Reference Citation Analysis]
111 Klionsky DJ, Petroni G, Amaravadi RK, Baehrecke EH, Ballabio A, Boya P, Bravo-San Pedro JM, Cadwell K, Cecconi F, Choi AMK, Choi ME, Chu CT, Codogno P, Colombo MI, Cuervo AM, Deretic V, Dikic I, Elazar Z, Eskelinen EL, Fimia GM, Gewirtz DA, Green DR, Hansen M, Jäättelä M, Johansen T, Juhász G, Karantza V, Kraft C, Kroemer G, Ktistakis NT, Kumar S, Lopez-Otin C, Macleod KF, Madeo F, Martinez J, Meléndez A, Mizushima N, Münz C, Penninger JM, Perera RM, Piacentini M, Reggiori F, Rubinsztein DC, Ryan KM, Sadoshima J, Santambrogio L, Scorrano L, Simon HU, Simon AK, Simonsen A, Stolz A, Tavernarakis N, Tooze SA, Yoshimori T, Yuan J, Yue Z, Zhong Q, Galluzzi L, Pietrocola F. Autophagy in major human diseases. EMBO J 2021;40:e108863. [PMID: 34459017 DOI: 10.15252/embj.2021108863] [Cited by in Crossref: 2] [Cited by in F6Publishing: 97] [Article Influence: 2.0] [Reference Citation Analysis]
112 Zhai Y, Wang J, Lang T, Kong Y, Rong R, Cai Y, Ran W, Xiong F, Zheng C, Wang Y, Yu Y, Zhu HH, Zhang P, Li Y. T lymphocyte membrane-decorated epigenetic nanoinducer of interferons for cancer immunotherapy. Nat Nanotechnol 2021;16:1271-80. [PMID: 34580467 DOI: 10.1038/s41565-021-00972-7] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
113 Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov 2021;2:468-83. [PMID: 34568832 DOI: 10.1158/2643-3230.bcd-21-0047] [Cited by in Crossref: 6] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
114 Nathansen J, Meyer F, Müller L, Schmitz M, Borgmann K, Dubrovska A. Beyond the Double-Strand Breaks: The Role of DNA Repair Proteins in Cancer Stem-Cell Regulation. Cancers (Basel) 2021;13:4818. [PMID: 34638302 DOI: 10.3390/cancers13194818] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
115 Audsley KM, Wagner T, Ta C, Newnes HV, Buzzai AC, Barnes SA, Wylie B, Armitage J, Kaisho T, Bosco A, McDonnell A, Cruickshank M, Fear VS, Foley B, Waithman J. IFNβ Is a Potent Adjuvant for Cancer Vaccination Strategies. Front Immunol 2021;12:735133. [PMID: 34552594 DOI: 10.3389/fimmu.2021.735133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
116 Li XY, Yao S, He YT, Ke SQ, Ma YF, Lu P, Nie SF, Wei SZ, Liang XJ, Liu L. Inflammation-Immunity-Nutrition Score: A Novel Prognostic Score for Patients with Resectable Colorectal Cancer. J Inflamm Res 2021;14:4577-88. [PMID: 34531673 DOI: 10.2147/JIR.S322260] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
117 Greene TT, Zuniga EI. Type I Interferon Induction and Exhaustion during Viral Infection: Plasmacytoid Dendritic Cells and Emerging COVID-19 Findings. Viruses 2021;13:1839. [PMID: 34578420 DOI: 10.3390/v13091839] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
118 Trono P, Tocci A, Musella M, Sistigu A, Nisticò P. Actin Cytoskeleton Dynamics and Type I IFN-Mediated Immune Response: A Dangerous Liaison in Cancer? Biology (Basel) 2021;10:913. [PMID: 34571790 DOI: 10.3390/biology10090913] [Reference Citation Analysis]
119 Fabian KP, Wolfson B, Hodge JW. From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment. Front Oncol 2021;11:728018. [PMID: 34497771 DOI: 10.3389/fonc.2021.728018] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
120 Dagher T, Maslah N, Edmond V, Cassinat B, Vainchenker W, Giraudier S, Pasquier F, Verger E, Niwa-Kawakita M, Lallemand-Breitenbach V, Plo I, Kiladjian JJ, Villeval JL, de Thé H. JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. J Exp Med 2021;218:e20201268. [PMID: 33075130 DOI: 10.1084/jem.20201268] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
121 Zhang F, Manna S, Pop LM, Chen ZJ, Fu YX, Hannan R. Type I Interferon Response in Radiation-Induced Anti-Tumor Immunity. Semin Radiat Oncol 2020;30:129-38. [PMID: 32381292 DOI: 10.1016/j.semradonc.2019.12.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
122 Huang FY, Wang JY, Dai SZ, Lin YY, Sun Y, Zhang L, Lu Z, Cao R, Tan GH. A recombinant oncolytic Newcastle virus expressing MIP-3α promotes systemic antitumor immunity. J Immunother Cancer 2020;8:e000330. [PMID: 32759233 DOI: 10.1136/jitc-2019-000330] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
123 Nam J, Son S, Park KS, Moon JJ. Photothermal therapy combined with neoantigen cancer vaccination for effective immunotherapy against large established tumors and distant metastasis. Adv Ther (Weinh) 2021;4:2100093. [PMID: 34485685 DOI: 10.1002/adtp.202100093] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
124 von Locquenghien M, Rozalén C, Celià-Terrassa T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest 2021;131:143296. [PMID: 33393507 DOI: 10.1172/JCI143296] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
125 Luo Y, Li L, Chen X, Gou H, Yan K, Xu Y. Effects of lactate in immunosuppression and inflammation: Progress and prospects. Int Rev Immunol 2021;:1-11. [PMID: 34486916 DOI: 10.1080/08830185.2021.1974856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
126 Wu Z, Liu K. Overview of vaccine adjuvants. Medicine in Drug Discovery 2021;11:100103. [DOI: 10.1016/j.medidd.2021.100103] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
127 Musella M, Galassi C, Manduca N, Sistigu A. The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. Biology (Basel) 2021;10:856. [PMID: 34571733 DOI: 10.3390/biology10090856] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
128 Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer 2020;8:e000337. [PMID: 32209603 DOI: 10.1136/jitc-2019-000337] [Cited by in Crossref: 131] [Cited by in F6Publishing: 231] [Article Influence: 131.0] [Reference Citation Analysis]
129 Liu X, Xu Y, Yin L, Hou Y, Zhao S. Chitosan-Poly(Acrylic Acid) Nanoparticles Loaded with R848 and MnCl2 Inhibit Melanoma via Regulating Macrophage Polarization and Dendritic Cell Maturation. Int J Nanomedicine 2021;16:5675-92. [PMID: 34456564 DOI: 10.2147/IJN.S318363] [Reference Citation Analysis]
130 Huang P, Zhu S, Liang X, Zhang Q, Liu C, Song L. Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs. Technol Cancer Res Treat 2021;20:15330338211038488. [PMID: 34431723 DOI: 10.1177/15330338211038488] [Reference Citation Analysis]
131 Zhang Y, Xie X, Yeganeh PN, Lee DJ, Valle-Garcia D, Meza-Sosa KF, Junqueira C, Su J, Luo HR, Hide W, Lieberman J. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown. Proc Natl Acad Sci U S A 2021;118:e2022830118. [PMID: 33627408 DOI: 10.1073/pnas.2022830118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
132 Geboers B, Timmer FEF, Ruarus AH, Pouw JEE, Schouten EAC, Bakker J, Puijk RS, Nieuwenhuizen S, Dijkstra M, van den Tol MP, de Vries JJJ, Oprea-Lager DE, Menke-van der Houven van Oordt CW, van der Vliet HJ, Wilmink JW, Scheffer HJ, de Gruijl TD, Meijerink MR, On Behalf Of The Dutch Pancreatic Cancer Group. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol. Cancers (Basel) 2021;13:3902. [PMID: 34359801 DOI: 10.3390/cancers13153902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
133 Parsels LA, Zhang Q, Karnak D, Parsels JD, Lam K, Willers H, Green MD, Rehemtulla A, Lawrence TS, Morgan MA. Translation of DNA Damage Response Inhibitors as Chemoradiation Sensitizers From the Laboratory to the Clinic. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02621-3. [PMID: 34348175 DOI: 10.1016/j.ijrobp.2021.07.1708] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
134 Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, Lu AZ, Molina JR, Minissale E, Swinger KK, Wigle TJ, Blackwell DJ, Majer CR, Ren Y, Niepel M, Varsamis ZA, Nayak SP, Bamberg E, Mo JR, Church WD, Mady ASA, Song J, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM, Keilhack H. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell 2021:S1535-6108(21)00340-8. [PMID: 34375612 DOI: 10.1016/j.ccell.2021.06.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
135 Lu P, Foley J, Zhu C, McNamara K, Sirinukunwattana K, Vennam S, Varma S, Fehri H, Srivastava A, Zhu S, Rittscher J, Mallick P, Curtis C, West R. Transcriptome and genome evolution during HER2-amplified breast neoplasia. Breast Cancer Res 2021;23:73. [PMID: 34266469 DOI: 10.1186/s13058-021-01451-6] [Reference Citation Analysis]
136 Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 2021;6:263. [PMID: 34248142 DOI: 10.1038/s41392-021-00658-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 114] [Article Influence: 1.0] [Reference Citation Analysis]
137 Hou Y, Liang HL, Yu X, Liu Z, Cao X, Rao E, Huang X, Wang L, Li L, Bugno J, Fu Y, Chmura SJ, Wu W, Luo SZ, Zheng W, Arina A, Jutzy J, McCall AR, Vokes EE, Pitroda SP, Fu YX, Weichselbaum RR. Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. Sci Transl Med 2021;13:eabb0130. [PMID: 33627484 DOI: 10.1126/scitranslmed.abb0130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
138 Bufalieri F, Basili I, Di Marcotullio L, Infante P. Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis. Front Mol Neurosci 2021;14:710171. [PMID: 34305530 DOI: 10.3389/fnmol.2021.710171] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
139 Guo P, Yang L, Zhang M, Zhang Y, Tong Y, Cao Y, Liu J. A Monocyte-Orchestrated IFN-I-to-IL-4 Cytokine Axis Instigates Protumoral Macrophages and Thwarts Poly(I:C) Therapy. J Immunol 2021:ji2001411. [PMID: 34193600 DOI: 10.4049/jimmunol.2001411] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
140 Zhang X, Wang S, Zhu Y, Zhang M, Zhao Y, Yan Z, Wang Q, Li X. Double-edged effects of interferons on the regulation of cancer-immunity cycle. Oncoimmunology 2021;10:1929005. [PMID: 34262796 DOI: 10.1080/2162402X.2021.1929005] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
141 Hargadon KM. The role of interferons in melanoma resistance to immune checkpoint blockade: mechanisms of escape and therapeutic implications. Br J Dermatol 2021. [PMID: 34185875 DOI: 10.1111/bjd.20608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
142 Varshney D, Qiu SY, Graf TP, McHugh KJ. Employing Drug Delivery Strategies to Overcome Challenges Using TLR7/8 Agonists for Cancer Immunotherapy. AAPS J 2021;23:90. [PMID: 34181117 DOI: 10.1208/s12248-021-00620-x] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
143 Li J, Ko JM, Dai W, Yu VZ, Ng HY, Hoffmann JS, Lung ML. Depletion of DNA Polymerase Theta Inhibits Tumor Growth and Promotes Genome Instability through the cGAS-STING-ISG Pathway in Esophageal Squamous Cell Carcinoma. Cancers (Basel) 2021;13:3204. [PMID: 34206946 DOI: 10.3390/cancers13133204] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
144 Grard M, Chatelain C, Delaunay T, Pons-Tostivint E, Bennouna J, Fonteneau JF. Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy. Front Oncol 2021;11:695770. [PMID: 34249754 DOI: 10.3389/fonc.2021.695770] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Jia DD, Niu Y, Zhu H, Wang S, Ma T, Li T. Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma. Front Oncol 2021;11:675873. [PMID: 34221994 DOI: 10.3389/fonc.2021.675873] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
146 Wijshake T, Zou Z, Chen B, Zhong L, Xiao G, Xie Y, Doench JG, Bennett L, Levine B. Tumor-suppressor function of Beclin 1 in breast cancer cells requires E-cadherin. Proc Natl Acad Sci U S A 2021;118:e2020478118. [PMID: 33495338 DOI: 10.1073/pnas.2020478118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
147 Wadowski B, Bueno R, De Rienzo A. Immune Microenvironment and Genetics in Malignant Pleural Mesothelioma. Front Oncol 2021;11:684025. [PMID: 34178677 DOI: 10.3389/fonc.2021.684025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
148 Kessler T, Wick W. Oncolytic virotherapy: Potentially a game-changing tumor treatment. Cancer Cell 2021;39:753-5. [PMID: 34129821 DOI: 10.1016/j.ccell.2021.05.014] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
149 Amouzegar A, Chelvanambi M, Filderman JN, Storkus WJ, Luke JJ. STING Agonists as Cancer Therapeutics. Cancers (Basel) 2021;13:2695. [PMID: 34070756 DOI: 10.3390/cancers13112695] [Cited by in Crossref: 2] [Cited by in F6Publishing: 29] [Article Influence: 2.0] [Reference Citation Analysis]
150 Neulinger-Muñoz M, Schaack D, Grekova SP, Bauer AS, Giese T, Salg GA, Espinet E, Leuchs B, Heller A, Nüesch JPF, Schenk M, Volkmar M, Giese NA. Human Retrotransposons and the Global Shutdown of Homeostatic Innate Immunity by Oncolytic Parvovirus H-1PV in Pancreatic Cancer. Viruses 2021;13:1019. [PMID: 34071585 DOI: 10.3390/v13061019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
151 Mao C, Beiss V, Fields J, Steinmetz NF, Fiering S. Cowpea mosaic virus stimulates antitumor immunity through recognition by multiple MYD88-dependent toll-like receptors. Biomaterials 2021;275:120914. [PMID: 34126409 DOI: 10.1016/j.biomaterials.2021.120914] [Cited by in Crossref: 1] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
152 Yasuma T, Toda M, Abdel-Hamid AM, D'Alessandro-Gabazza C, Kobayashi T, Nishihama K, D'Alessandro VF, Pereira GV, Mackie RI, Gabazza EC, Cann I. Degradation Products of Complex Arabinoxylans by Bacteroides intestinalis Enhance the Host Immune Response. Microorganisms 2021;9:1126. [PMID: 34067445 DOI: 10.3390/microorganisms9061126] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
153 Zong Z, Wei Y, Ren J, Zhang L, Zhou F. The intersection of COVID-19 and cancer: signaling pathways and treatment implications. Mol Cancer 2021;20:76. [PMID: 34001144 DOI: 10.1186/s12943-021-01363-1] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
154 Shamseddine AA, Burman B, Lee NY, Zamarin D, Riaz N. Tumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer Discov 2021;11:1896-912. [PMID: 33990345 DOI: 10.1158/2159-8290.CD-20-1760] [Cited by in Crossref: 1] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
155 McElrath C, Espinosa V, Lin JD, Peng J, Sridhar R, Dutta O, Tseng HC, Smirnov SV, Risman H, Sandoval MJ, Davra V, Chang YJ, Pollack BP, Birge RB, Galan M, Rivera A, Durbin JE, Kotenko SV. Critical role of interferons in gastrointestinal injury repair. Nat Commun 2021;12:2624. [PMID: 33976143 DOI: 10.1038/s41467-021-22928-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
156 van Wilpe S, Tolmeijer SH, Koornstra RHT, de Vries IJM, Gerritsen WR, Ligtenberg M, Mehra N. Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. Cancers (Basel) 2021;13:2249. [PMID: 34067105 DOI: 10.3390/cancers13092249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
157 Hangai S, Kimura Y, Taniguchi T, Yanai H. Signal-transducing innate receptors in tumor immunity. Cancer Sci 2021;112:2578-91. [PMID: 33570784 DOI: 10.1111/cas.14848] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
158 Pu C, Tao S, Xu J, Huang M. Harnessing Genomic Stress for Antitumor Immunity. Antioxidants & Redox Signaling 2021;34:1128-50. [DOI: 10.1089/ars.2020.8221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
159 Balka KR, Louis C, Saunders TL, Smith AM, Calleja DJ, D'Silva DB, Moghaddas F, Tailler M, Lawlor KE, Zhan Y, Burns CJ, Wicks IP, Miner JJ, Kile BT, Masters SL, De Nardo D. TBK1 and IKKε Act Redundantly to Mediate STING-Induced NF-κB Responses in Myeloid Cells. Cell Rep 2020;31:107492. [PMID: 32268090 DOI: 10.1016/j.celrep.2020.03.056] [Cited by in Crossref: 39] [Cited by in F6Publishing: 83] [Article Influence: 39.0] [Reference Citation Analysis]
160 Yan X, Xie Y, Yang F, Hua Y, Zeng T, Sun C, Yang M, Huang X, Wu H, Fu Z, Li W, Jiao S, Yin Y. Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis. J Exp Clin Cancer Res 2021;40:142. [PMID: 33906694 DOI: 10.1186/s13046-021-01949-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
161 Ioannou N, Hagner PR, Stokes M, Gandhi AK, Apollonio B, Fanous M, Papazoglou D, Sutton LA, Rosenquist R, Amini RM, Chiu H, Lopez-Girona A, Janardhanan P, Awan FT, Jones J, Kay NE, Shanafelt TD, Tallman MS, Stamatopoulos K, Patten PEM, Vardi A, Ramsay AG. Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy. Blood 2021;137:216-31. [PMID: 33024998 DOI: 10.1182/blood.2020006073] [Cited by in Crossref: 7] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
162 Falahat R, Berglund A, Putney RM, Perez-Villarroel P, Aoyama S, Pilon-Thomas S, Barber GN, Mulé JJ. Epigenetic reprogramming of tumor cell-intrinsic STING function sculpts antigenicity and T cell recognition of melanoma. Proc Natl Acad Sci U S A 2021;118:e2013598118. [PMID: 33827917 DOI: 10.1073/pnas.2013598118] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
163 Suter MA, Tan NY, Thiam CH, Khatoo M, MacAry PA, Angeli V, Gasser S, Zhang YL. cGAS-STING cytosolic DNA sensing pathway is suppressed by JAK2-STAT3 in tumor cells. Sci Rep 2021;11:7243. [PMID: 33790360 DOI: 10.1038/s41598-021-86644-x] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
164 Lasho T, Patnaik MM. Novel therapeutic targets for chronic myelomonocytic leukemia. Best Pract Res Clin Haematol 2021;34:101244. [PMID: 33762099 DOI: 10.1016/j.beha.2021.101244] [Reference Citation Analysis]
165 Takahashi M, Lio CJ, Campeau A, Steger M, Ay F, Mann M, Gonzalez DJ, Jain M, Sharma S. The tumor suppressor kinase DAPK3 drives tumor-intrinsic immunity through the STING-IFN-β pathway. Nat Immunol 2021;22:485-96. [PMID: 33767426 DOI: 10.1038/s41590-021-00896-3] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
166 Brown MC, Mosaheb MM, Mohme M, McKay ZP, Holl EK, Kastan JP, Yang Y, Beasley GM, Hwang ES, Ashley DM, Bigner DD, Nair SK, Gromeier M. Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling. Nat Commun 2021;12:1858. [PMID: 33767151 DOI: 10.1038/s41467-021-22088-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
167 Apollonio B, Ioannou N, Papazoglou D, Ramsay AG. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. Front Oncol 2021;11:626818. [PMID: 33842331 DOI: 10.3389/fonc.2021.626818] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
168 Zhang R, Wang C, Guan Y, Wei X, Sha M, Yi M, Jing M, Lv M, Guo W, Xu J, Wan Y, Jia XM, Jiang Z. Manganese salts function as potent adjuvants. Cell Mol Immunol 2021;18:1222-34. [PMID: 33767434 DOI: 10.1038/s41423-021-00669-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
169 McWhirter SM, Jefferies CA. Nucleic Acid Sensors as Therapeutic Targets for Human Disease. Immunity 2020;53:78-97. [PMID: 32668230 DOI: 10.1016/j.immuni.2020.04.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
170 Najjar YG, McCurry D, Lin H, Lin Y, Zang Y, Davar D, Karunamurthy A, Drabick JJ, Neves RI, Butterfield LH, Ernstoff MS, Puzanov I, Skitzki JJ, Bordeaux J, Summit IB, Bender JO, Kim JY, Chen B, Sarikonda G, Pahuja A, Tsau J, Alfonso Z, Laing C, Pingpank JF, Holtzman MP, Sander C, Rose A, Zarour HM, Kirkwood JM, Tarhini AA. Neoadjuvant Pembrolizumab and High-Dose IFNα-2b in Resectable Regionally Advanced Melanoma. Clin Cancer Res 2021;27:4195-204. [PMID: 33753453 DOI: 10.1158/1078-0432.CCR-20-4301] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
171 Wu MS, Kuo YP, Lo YC, Tsai DJ, Lai CY, Chuang TH, Lin SY, Tsai WT, Chung PJ, Yu GY. Type I Interferon Signaling Accelerates Liver Regeneration by Metabolic Modulation in Noninfectious Conditions. Am J Pathol 2021;191:1036-48. [PMID: 33753025 DOI: 10.1016/j.ajpath.2021.03.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
172 Alicea-Torres K, Sanseviero E, Gui J, Chen J, Veglia F, Yu Q, Donthireddy L, Kossenkov A, Lin C, Fu S, Mulligan C, Nam B, Masters G, Denstman F, Bennett J, Hockstein N, Rynda-Apple A, Nefedova Y, Fuchs SY, Gabrilovich DI. Immune suppressive activity of myeloid-derived suppressor cells in cancer requires inactivation of the type I interferon pathway. Nat Commun 2021;12:1717. [PMID: 33741967 DOI: 10.1038/s41467-021-22033-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
173 Shinchi H, Yuki M, Yamauchi T, Niimura M, Wakao M, Cottam HB, Hayashi T, Carson DA, Moroishi T, Suda Y. Glyco-Nanoadjuvants: Sugar Structures on Carriers of a Small Molecule TLR7 Ligand Affect Their Immunostimulatory Activities. ACS Appl Bio Mater 2021;4:2732-41. [PMID: 35014312 DOI: 10.1021/acsabm.0c01639] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
174 Goncalves A, Mezni E, Bertucci F. Combining poly(ADP-ribose) polymerase inhibitors and immune checkpoint inhibitors in breast cancer: rationale and preliminary clinical results. Curr Opin Oncol 2020;32:585-93. [PMID: 32852311 DOI: 10.1097/CCO.0000000000000680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
175 Wang C, Sun Z, Zhao C, Zhang Z, Wang H, Liu Y, Guo Y, Zhang B, Gu L, Yu Y, Hu Y, Wu J. Maintaining manganese in tumor to activate cGAS-STING pathway evokes a robust abscopal anti-tumor effect. J Control Release 2021;331:480-90. [PMID: 33545219 DOI: 10.1016/j.jconrel.2021.01.036] [Cited by in Crossref: 4] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
176 Alfino LN, Wilczewski-Shirai KC, Cronise KE, Coy J, Glapa K, Ehrhart EJ, Charles JB, Duval DL, Regan DP. Role of Periostin Expression in Canine Osteosarcoma Biology and Clinical Outcome. Vet Pathol 2021;58:981-93. [PMID: 33685296 DOI: 10.1177/0300985821996671] [Reference Citation Analysis]
177 Fenton SE, Saleiro D, Platanias LC. Type I and II Interferons in the Anti-Tumor Immune Response. Cancers (Basel) 2021;13:1037. [PMID: 33801234 DOI: 10.3390/cancers13051037] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
178 Deretic V. Autophagy in inflammation, infection, and immunometabolism. Immunity 2021;54:437-53. [PMID: 33691134 DOI: 10.1016/j.immuni.2021.01.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 70] [Article Influence: 18.0] [Reference Citation Analysis]
179 Lin RA, Lin JK, Lin S. Mechanisms of immunogenic cell death and immune checkpoint blockade therapy. The Kaohsiung Journal of Medical Sciences 2021;37:448-58. [DOI: 10.1002/kjm2.12375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
180 Wu Y, Biswas D, Swanton C. Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Semin Cancer Biol 2021:S1044-579X(21)00042-0. [PMID: 33631295 DOI: 10.1016/j.semcancer.2021.02.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
181 Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 2021;6:72. [PMID: 33608497 DOI: 10.1038/s41392-020-00449-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 64] [Article Influence: 2.0] [Reference Citation Analysis]
182 Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, An C, Luu YT, Song S, Yap TA, Ajani JA, Mills GB, Shen X, Peng G. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest 2020;130:5951-66. [PMID: 33016929 DOI: 10.1172/JCI130445] [Cited by in Crossref: 11] [Cited by in F6Publishing: 30] [Article Influence: 11.0] [Reference Citation Analysis]
183 Wang L, Ning S. TRIMming Type I Interferon-Mediated Innate Immune Response in Antiviral and Antitumor Defense. Viruses 2021;13:279. [PMID: 33670221 DOI: 10.3390/v13020279] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
184 Kim YE, Kim EK, Song MJ, Kim TY, Jang HH, Kang D. SILAC-Based Quantitative Proteomic Analysis of Oxaliplatin-Resistant Pancreatic Cancer Cells. Cancers (Basel) 2021;13:724. [PMID: 33578797 DOI: 10.3390/cancers13040724] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
185 Li S, Luo M, Wang Z, Feng Q, Wilhelm J, Wang X, Li W, Wang J, Cholka A, Fu YX, Sumer BD, Yu H, Gao J. Prolonged activation of innate immune pathways by a polyvalent STING agonist. Nat Biomed Eng 2021;5:455-66. [PMID: 33558734 DOI: 10.1038/s41551-020-00675-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
186 Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, Hsu JL, Chou CW, Sun X, Deng Y, Chou CK, Yu D, Hung MC. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat Commun 2021;12:832. [PMID: 33547304 DOI: 10.1038/s41467-021-21099-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
187 Peignier A, Parker D. Impact of Type I Interferons on Susceptibility to Bacterial Pathogens. Trends Microbiol 2021;29:823-35. [PMID: 33546974 DOI: 10.1016/j.tim.2021.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
188 Kim CW, Kim K, Lee HK. The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets. BMB Rep 2021;54:31-43. [DOI: 10.5483/bmbrep.2021.54.1.224] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
189 Lucarini V, Melaiu O, Tempora P, D'Amico S, Locatelli F, Fruci D. Dendritic Cells: Behind the Scenes of T-Cell Infiltration into the Tumor Microenvironment. Cancers (Basel) 2021;13:433. [PMID: 33498755 DOI: 10.3390/cancers13030433] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
190 Hu Q, Zhou Q, Xia X, Shao L, Wang M, Lu X, Liu S, Guan W. Cytosolic sensor STING in mucosal immunity: a master regulator of gut inflammation and carcinogenesis. J Exp Clin Cancer Res 2021;40:39. [PMID: 33485379 DOI: 10.1186/s13046-021-01850-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
191 Accogli T, Bruchard M, Végran F. Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment. Cancers (Basel) 2021;13:373. [PMID: 33498483 DOI: 10.3390/cancers13030373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
192 Mehdizadeh R, Shariatpanahi SP, Goliaei B, Peyvandi S, Rüegg C. Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer. Cancers (Basel) 2021;13:E245. [PMID: 33440806 DOI: 10.3390/cancers13020245] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
193 Tandon V, de la Vega L, Banerjee S. Emerging roles of DYRK2 in cancer. J Biol Chem 2021;296:100233. [PMID: 33376136 DOI: 10.1074/jbc.REV120.015217] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
194 Gessani S, Belardelli F. Type I Interferons as Joint Regulators of Tumor Growth and Obesity. Cancers (Basel) 2021;13:E196. [PMID: 33430520 DOI: 10.3390/cancers13020196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
195 Huang HW, Chang CC, Wang CS, Lin KH. Association between Inflammation and Function of Cell Adhesion Molecules Influence on Gastrointestinal Cancer Development. Cells 2021;10:E67. [PMID: 33406733 DOI: 10.3390/cells10010067] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
196 Nicolai CJ, Wolf N, Chang IC, Kirn G, Marcus A, Ndubaku CO, McWhirter SM, Raulet DH. NK cells mediate clearance of CD8+ T cell-resistant tumors in response to STING agonists. Sci Immunol 2020;5:eaaz2738. [PMID: 32198222 DOI: 10.1126/sciimmunol.aaz2738] [Cited by in Crossref: 33] [Cited by in F6Publishing: 63] [Article Influence: 16.5] [Reference Citation Analysis]
197 Roy ER, Wang B, Wan YW, Chiu G, Cole A, Yin Z, Propson NE, Xu Y, Jankowsky JL, Liu Z, Lee VM, Trojanowski JQ, Ginsberg SD, Butovsky O, Zheng H, Cao W. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest 2020;130:1912-30. [PMID: 31917687 DOI: 10.1172/JCI133737] [Cited by in Crossref: 65] [Cited by in F6Publishing: 98] [Article Influence: 32.5] [Reference Citation Analysis]
198 Luo X, Donnelly CR, Gong W, Heath BR, Hao Y, Donnelly LA, Moghbeli T, Tan YS, Lin X, Bellile E, Kansy BA, Carey TE, Brenner JC, Cheng L, Polverini PJ, Morgan MA, Wen H, Prince ME, Ferris RL, Xie Y, Young S, Wolf GT, Chen Q, Lei YL. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J Clin Invest 2020;130:1635-52. [PMID: 31874109 DOI: 10.1172/JCI129497] [Cited by in Crossref: 33] [Cited by in F6Publishing: 46] [Article Influence: 16.5] [Reference Citation Analysis]
199 Qiu CC, Kotredes KP, Cremers T, Patel S, Afanassiev A, Slifker M, Gallucci S, Gamero AM. Targeted Stat2 deletion in conventional dendritic cells impairs CTL responses but does not affect antibody production. Oncoimmunology 2020;10:1860477. [PMID: 33457079 DOI: 10.1080/2162402X.2020.1860477] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
200 Ho-Xuan H, Lehmann G, Glazar P, Gypas F, Eichner N, Heizler K, Schlitt HJ, Zavolan M, Rajewsky N, Meister G, Hackl C. Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy. Cancers (Basel) 2020;13:E49. [PMID: 33375322 DOI: 10.3390/cancers13010049] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
201 Zhan X, Guo S, Li Y, Ran H, Huang H, Mi L, Wu J, Wang X, Xiao D, Chen L, Li D, Zhang S, Yan X, Yu Y, Li T, Han Q, He K, Cui J, Li T, Zhou T, Rich JN, Bao S, Zhang X, Li A, Man J. Glioma stem-like cells evade interferon suppression through MBD3/NuRD complex-mediated STAT1 downregulation. J Exp Med 2020;217:e20191340. [PMID: 32181805 DOI: 10.1084/jem.20191340] [Cited by in Crossref: 11] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
202 Liu Y, Li K, Zhu WB, Zhang H, Huang WT, Liu XC, Lin Y, Cai J, Yan GM, Qiu JG, Peng L, Liang JK, Hu C. Suppression of CCDC6 sensitizes tumor to oncolytic virus M1. Neoplasia 2021;23:158-68. [PMID: 33338804 DOI: 10.1016/j.neo.2020.12.003] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
203 Checcoli A, Pol JG, Naldi A, Noel V, Barillot E, Kroemer G, Thieffry D, Calzone L, Stoll G. Dynamical Boolean Modeling of Immunogenic Cell Death. Front Physiol 2020;11:590479. [PMID: 33281620 DOI: 10.3389/fphys.2020.590479] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
204 Zahid A, Ismail H, Li B, Jin T. Molecular and Structural Basis of DNA Sensors in Antiviral Innate Immunity. Front Immunol 2020;11:613039. [PMID: 33329609 DOI: 10.3389/fimmu.2020.613039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
205 Sasso E, D'Alise AM, Zambrano N, Scarselli E, Folgori A, Nicosia A. New viral vectors for infectious diseases and cancer. Semin Immunol 2020;50:101430. [PMID: 33262065 DOI: 10.1016/j.smim.2020.101430] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
206 Manna S, Maiti S, Shen J, Du W, Esser-Kahn AP. Pathogen-like Nanoassemblies of Covalently Linked TLR Agonists Enhance CD8 and NK Cell-Mediated Antitumor Immunity. ACS Cent Sci 2020;6:2071-8. [PMID: 33274283 DOI: 10.1021/acscentsci.0c01001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
207 Sosa Cuevas E, Ouaguia L, Mouret S, Charles J, De Fraipont F, Manches O, Valladeau-Guilemond J, Bendriss-Vermare N, Chaperot L, Aspord C. BDCA1+ cDC2s, BDCA2+ pDCs and BDCA3+ cDC1s reveal distinct pathophysiologic features and impact on clinical outcomes in melanoma patients. Clin Transl Immunology 2020;9:e1190. [PMID: 33282290 DOI: 10.1002/cti2.1190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
208 Storozynsky Q, Hitt MM. The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer. Int J Mol Sci 2020;21:E8877. [PMID: 33238631 DOI: 10.3390/ijms21228877] [Cited by in Crossref: 6] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
209 Chen M, Hu S, Li Y, Jiang TT, Jin H, Feng L. Targeting nuclear acid-mediated immunity in cancer immune checkpoint inhibitor therapies. Signal Transduct Target Ther 2020;5:270. [PMID: 33214545 DOI: 10.1038/s41392-020-00347-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
210 Wang X, Wilhelm J, Li W, Li S, Wang Z, Huang G, Wang J, Tang H, Khorsandi S, Sun Z, Evers B, Gao J. Polycarbonate-based ultra-pH sensitive nanoparticles improve therapeutic window. Nat Commun 2020;11:5828. [PMID: 33203928 DOI: 10.1038/s41467-020-19651-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
211 Huang X, Tang T, Zhang G, Hong Z, Xu J, Yadav DK, Bai X, Liang T. Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. NPJ Precis Oncol 2020;4:29. [PMID: 33299118 DOI: 10.1038/s41698-020-00136-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
212 Li Y, Song Y, Li P, Li M, Wang H, Xu T, Yu X, Yu Y, Tai Y, Chen P, Cai X, Wang X, Xiang L, Deng R, Zhang X, Gao L, Wang X, Liu J, Cao F. Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma. J Immunother Cancer 2020;8:e000111. [PMID: 32152220 DOI: 10.1136/jitc-2019-000111] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
213 Mao J, Cao M, Zhang F, Zhang J, Duan X, Lu L, Yang Z, Zhang X, Zhu W, Zhang Q, Wang Z, Shen J. Peritumoral administration of IFNβ upregulated mesenchymal stem cells inhibits tumor growth in an orthotopic, immunocompetent rat glioma model. J Immunother Cancer 2020;8:e000164. [PMID: 32169868 DOI: 10.1136/jitc-2019-000164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
214 Pol JG, Workenhe ST, Konda P, Gujar S, Kroemer G. Cytokines in oncolytic virotherapy. Cytokine Growth Factor Rev 2020;56:4-27. [PMID: 33183957 DOI: 10.1016/j.cytogfr.2020.10.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
215 Plavc G, Jesenko T, Oražem M, Strojan P. Challenges in Combining Immunotherapy with Radiotherapy in Recurrent/Metastatic Head and Neck Cancer. Cancers (Basel) 2020;12:E3197. [PMID: 33143094 DOI: 10.3390/cancers12113197] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
216 Huerga Encabo H, Traveset L, Argilaguet J, Angulo A, Nistal-Villán E, Jaiswal R, Escalante CR, Gekas C, Meyerhans A, Aramburu J, López-Rodríguez C. The transcription factor NFAT5 limits infection-induced type I interferon responses. J Exp Med 2020;217:e20190449. [PMID: 31816635 DOI: 10.1084/jem.20190449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
217 Miar A, Arnaiz E, Bridges E, Beedie S, Cribbs AP, Downes DJ, Beagrie RA, Rehwinkel J, Harris AL. Hypoxia Induces Transcriptional and Translational Downregulation of the Type I IFN Pathway in Multiple Cancer Cell Types. Cancer Res 2020;80:5245-56. [PMID: 33115807 DOI: 10.1158/0008-5472.CAN-19-2306] [Cited by in Crossref: 5] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
218 Seelig A. P-Glycoprotein: One Mechanism, Many Tasks and the Consequences for Pharmacotherapy of Cancers. Front Oncol 2020;10:576559. [PMID: 33194688 DOI: 10.3389/fonc.2020.576559] [Cited by in Crossref: 5] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
219 Lapenta C, Gabriele L, Santini SM. IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives. Vaccines (Basel) 2020;8:E617. [PMID: 33086492 DOI: 10.3390/vaccines8040617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
220 Yu W, Hao X, Li Y, Yang C, Li Y, He Z, Huang F. Vertical transmission of hepatitis E virus in pregnant rhesus macaques. Sci Rep 2020;10:17517. [PMID: 33060782 DOI: 10.1038/s41598-020-74461-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
221 Lin H, Lian J, Xia L, Guan G, You J. CBX3 Promotes Gastric Cancer Progression and Affects Factors Related to Immunotherapeutic Responses. Cancer Manag Res 2020;12:10113-25. [PMID: 33116867 DOI: 10.2147/CMAR.S271807] [Cited by in Crossref: 3] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
222 Riemann D, Schütte W, Turzer S, Seliger B, Möller M. High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy. Cancers (Basel) 2020;12:E2966. [PMID: 33066260 DOI: 10.3390/cancers12102966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
223 Plavc G, Strojan P. Combining radiotherapy and immunotherapy in definitive treatment of head and neck squamous cell carcinoma: review of current clinical trials. Radiol Oncol 2020;54:377-93. [PMID: 33064670 DOI: 10.2478/raon-2020-0060] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
224 Liang P, Wang G, Liu X, Wang Z, Wang J, Gao W. Spatiotemporal combination of thermosensitive polypeptide fused interferon and temozolomide for post-surgical glioblastoma immunochemotherapy. Biomaterials 2021;264:120447. [PMID: 33069137 DOI: 10.1016/j.biomaterials.2020.120447] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
225 Derosa L, Melenotte C, Griscelli F, Gachot B, Marabelle A, Kroemer G, Zitvogel L. The immuno-oncological challenge of COVID-19. Nat Cancer 2020;1:946-64. [DOI: 10.1038/s43018-020-00122-3] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 14.0] [Reference Citation Analysis]
226 Biterge Süt B. Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13. Life Sci 2020;258:118170. [PMID: 32735883 DOI: 10.1016/j.lfs.2020.118170] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
227 Zhang Y, Deng Y, Yang X, Xue H, Lang Y. The Relationship Between Protein S-Nitrosylation and Human Diseases: A Review. Neurochem Res 2020;45:2815-27. [PMID: 32984933 DOI: 10.1007/s11064-020-03136-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
228 Jia H, Mo W, Hong M, Jiang S, Zhang YY, He D, Yu D, Shi Y, Cao J, Xu X, Zhang S. Interferon-α inducible protein 6 (IFI6) confers protection against ionizing radiation in skin cells. J Dermatol Sci 2020;100:139-47. [PMID: 33059972 DOI: 10.1016/j.jdermsci.2020.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
229 Tsuchiya N, Zhang R, Iwama T, Ueda N, Liu T, Tatsumi M, Sasaki Y, Shimoda R, Osako Y, Sawada Y, Kubo Y, Miyashita A, Fukushima S, Cheng Z, Nakaki R, Takubo K, Okada S, Kaneko S, Ihn H, Kaisho T, Nishimura Y, Senju S, Endo I, Nakatsura T, Uemura Y. Type I Interferon Delivery by iPSC-Derived Myeloid Cells Elicits Antitumor Immunity via XCR1+ Dendritic Cells. Cell Rep 2019;29:162-175.e9. [PMID: 31577946 DOI: 10.1016/j.celrep.2019.08.086] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 7.5] [Reference Citation Analysis]
230 Greene TT, Jo YR, Zuniga EI. Infection and cancer suppress pDC derived IFN-I. Curr Opin Immunol 2020;66:114-22. [PMID: 32947131 DOI: 10.1016/j.coi.2020.08.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
231 Van Hoecke L, Roose K, Ballegeer M, Zhong Z, Sanders NN, De Koker S, Saelens X, Van Lint S. The Opposing Effect of Type I IFN on the T Cell Response by Non-modified mRNA-Lipoplex Vaccines Is Determined by the Route of Administration. Mol Ther Nucleic Acids 2020;22:373-81. [PMID: 33230442 DOI: 10.1016/j.omtn.2020.09.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
232 Horvath L, Thienpont B, Zhao L, Wolf D, Pircher A. Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook. Mol Cancer 2020;19:141. [PMID: 32917214 DOI: 10.1186/s12943-020-01260-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 58] [Article Influence: 10.5] [Reference Citation Analysis]
233 Wang Z, Guo J, Liu X, Sun J, Gao W. Temperature-triggered micellization of interferon alpha-diblock copolypeptide conjugate with enhanced stability and pharmacology. J Control Release 2020;328:444-53. [PMID: 32898593 DOI: 10.1016/j.jconrel.2020.08.065] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
234 Kepp O, Kroemer G. Pseudovirus for immunotherapy. Nat Cancer 2020;1:860-1. [PMID: 35121951 DOI: 10.1038/s43018-020-00107-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
235 Oliver AJ, Keam SP, von Scheidt B, Zanker DJ, Harrison AJ, Tantalo DG, Darcy PK, Kershaw MH, Slaney CY. Primary and metastatic breast tumors cross-talk to influence immunotherapy responses. Oncoimmunology 2020;9:1802979. [PMID: 32939322 DOI: 10.1080/2162402X.2020.1802979] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
236 Liang J, Wang H, Ding W, Huang J, Zhou X, Wang H, Dong X, Li G, Chen E, Zhou F, Fan H, Xia J, Shen B, Cai D, Lan P, Jiang H, Ling J, Cheng Z, Liu X, Sun J. Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity. Sci Adv 2020;6:eabc3646. [PMID: 32923651 DOI: 10.1126/sciadv.abc3646] [Cited by in Crossref: 14] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
237 Lv M, Chen M, Zhang R, Zhang W, Wang C, Zhang Y, Wei X, Guan Y, Liu J, Feng K, Jing M, Wang X, Liu YC, Mei Q, Han W, Jiang Z. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell Res 2020;30:966-79. [PMID: 32839553 DOI: 10.1038/s41422-020-00395-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 98] [Article Influence: 15.5] [Reference Citation Analysis]
238 Damasceno PKF, de Santana TA, Santos GC, Orge ID, Silva DN, Albuquerque JF, Golinelli G, Grisendi G, Pinelli M, Ribeiro Dos Santos R, Dominici M, Soares MBP. Genetic Engineering as a Strategy to Improve the Therapeutic Efficacy of Mesenchymal Stem/Stromal Cells in Regenerative Medicine. Front Cell Dev Biol 2020;8:737. [PMID: 32974331 DOI: 10.3389/fcell.2020.00737] [Cited by in Crossref: 5] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
239 Smith AAA, Gale EC, Roth GA, Maikawa CL, Correa S, Yu AC, Appel EA. Nanoparticles Presenting Potent TLR7/8 Agonists Enhance Anti-PD-L1 Immunotherapy in Cancer Treatment. Biomacromolecules 2020;21:3704-12. [PMID: 32816460 DOI: 10.1021/acs.biomac.0c00812] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
240 Reisländer T, Groelly FJ, Tarsounas M. DNA Damage and Cancer Immunotherapy: A STING in the Tale. Mol Cell 2020;80:21-8. [PMID: 32810436 DOI: 10.1016/j.molcel.2020.07.026] [Cited by in Crossref: 21] [Cited by in F6Publishing: 68] [Article Influence: 10.5] [Reference Citation Analysis]
241 Sagnella SM, Yang L, Stubbs GE, Boslem E, Martino-Echarri E, Smolarczyk K, Pattison SL, Vanegas N, St Clair E, Clarke S, Boockvar J, MacDiarmid JA, Brahmbhatt H. Cyto-Immuno-Therapy for Cancer: A Pathway Elicited by Tumor-Targeted, Cytotoxic Drug-Packaged Bacterially Derived Nanocells. Cancer Cell 2020;37:354-370.e7. [PMID: 32183951 DOI: 10.1016/j.ccell.2020.02.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
242 Stok JE, Vega Quiroz ME, van der Veen AG. Self RNA Sensing by RIG-I–like Receptors in Viral Infection and Sterile Inflammation. J I 2020;205:883-91. [DOI: 10.4049/jimmunol.2000488] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
243 Cai J, Liu W, Wong CW, Zhu W, Lin Y, Hu J, Xu W, Zhang J, Sander M, Wang Z, Dan J, Zhang J, Liu Y, Guo L, Qin Z, Liu X, Liu Y, Yan G, Wu S, Liang J. Zinc-finger antiviral protein acts as a tumor suppressor in colorectal cancer. Oncogene 2020;39:5995-6008. [PMID: 32770142 DOI: 10.1038/s41388-020-01416-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
244 Fucikova J, Spisek R, Kroemer G, Galluzzi L. Calreticulin and cancer. Cell Res 2021;31:5-16. [PMID: 32733014 DOI: 10.1038/s41422-020-0383-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 39] [Article Influence: 6.5] [Reference Citation Analysis]
245 D'Anna F, Van Dyck L, Xiong J, Zhao H, Berrens RV, Qian J, Bieniasz-Krzywiec P, Chandra V, Schoonjans L, Matthews J, De Smedt J, Minnoye L, Amorim R, Khorasanizadeh S, Yu Q, Zhao L, De Borre M, Savvides SN, Simon MC, Carmeliet P, Reik W, Rastinejad F, Mazzone M, Thienpont B, Lambrechts D. DNA methylation repels binding of hypoxia-inducible transcription factors to maintain tumor immunotolerance. Genome Biol 2020;21:182. [PMID: 32718321 DOI: 10.1186/s13059-020-02087-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
246 Kumari P, Russo AJ, Shivcharan S, Rathinam VA. AIM2 in health and disease: Inflammasome and beyond. Immunol Rev 2020;297:83-95. [PMID: 32713036 DOI: 10.1111/imr.12903] [Cited by in Crossref: 13] [Cited by in F6Publishing: 35] [Article Influence: 6.5] [Reference Citation Analysis]
247 Tagawa H, Kanemaru H, Kimura T, Kuriyama H, Sawamura S, Kajihara I, Miyashita A, Aoi J, Fukushima S, Ihn H. BATF2 expression as a novel marker for invasive phenotype in malignant melanoma. J Dermatol 2020;47:e372-3. [PMID: 32696470 DOI: 10.1111/1346-8138.15495] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
248 Frega G, Wu Q, Le Naour J, Vacchelli E, Galluzzi L, Kroemer G, Kepp O. Trial Watch: experimental TLR7/TLR8 agonists for oncological indications. Oncoimmunology 2020;9:1796002. [PMID: 32934889 DOI: 10.1080/2162402X.2020.1796002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
249 Wedenoja S, Yoshihara M, Teder H, Sariola H, Gissler M, Katayama S, Wedenoja J, Häkkinen IM, Ezer S, Linder N, Lundin J, Skoog T, Sahlin E, Iwarsson E, Pettersson K, Kajantie E, Mokkonen M, Heinonen S, Laivuori H, Krjutškov K, Kere J. Fetal HLA-G mediated immune tolerance and interferon response in preeclampsia. EBioMedicine 2020;59:102872. [PMID: 32680723 DOI: 10.1016/j.ebiom.2020.102872] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
250 Lohmann B, Silginer M, Picard D, Schneider H, Remke M, Roth P, Reifenberger G, Weller M. Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity. Neurooncol Adv 2020;2:vdaa043. [PMID: 32642697 DOI: 10.1093/noajnl/vdaa043] [Reference Citation Analysis]
251 Liu P, Zhao L, Ferrere G, Alves-Costa-Silva C, Ly P, Wu Q, Tian AL, Derosa L, Zitvogel L, Kepp O, Kroemer G. Combination treatments with hydroxychloroquine and azithromycin are compatible with the therapeutic induction of anticancer immune responses. Oncoimmunology 2020;9:1789284. [PMID: 32923151 DOI: 10.1080/2162402X.2020.1789284] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
252 Holmström MO, Hasselbalch HC, Andersen MH. Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms. Cancers (Basel) 2020;12:E1763. [PMID: 32630667 DOI: 10.3390/cancers12071763] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
253 Van Herck S, De Geest BG. Nanomedicine-mediated alteration of the pharmacokinetic profile of small molecule cancer immunotherapeutics. Acta Pharmacol Sin 2020;41:881-94. [PMID: 32451411 DOI: 10.1038/s41401-020-0425-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
254 Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol 2020;17:807-21. [PMID: 32612154 DOI: 10.1038/s41423-020-0488-6] [Cited by in Crossref: 66] [Cited by in F6Publishing: 230] [Article Influence: 33.0] [Reference Citation Analysis]
255 Auletta JJ, Adamson PC, Agin JE, Kearns P, Kennedy S, Kieran MW, Ludwinski DM, Knox LJ, McKay K, Rhiner P, Thiele CJ, Cripe TP. Pediatric cancer research: Surviving COVID-19. Pediatr Blood Cancer 2020;67:e28435. [PMID: 32558190 DOI: 10.1002/pbc.28435] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
256 Le Naour J, Zitvogel L, Galluzzi L, Vacchelli E, Kroemer G. Trial watch: STING agonists in cancer therapy. Oncoimmunology 2020;9:1777624. [PMID: 32934881 DOI: 10.1080/2162402X.2020.1777624] [Cited by in Crossref: 31] [Cited by in F6Publishing: 64] [Article Influence: 15.5] [Reference Citation Analysis]
257 Peyraud F, Italiano A. Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors. Cancers (Basel) 2020;12:E1502. [PMID: 32526888 DOI: 10.3390/cancers12061502] [Cited by in Crossref: 31] [Cited by in F6Publishing: 64] [Article Influence: 15.5] [Reference Citation Analysis]
258 Menendez D, Snipe J, Marzec J, Innes CL, Polack FP, Caballero MT, Schurman SH, Kleeberger SR, Resnick MA. p53-responsive TLR8 SNP enhances human innate immune response to respiratory syncytial virus. J Clin Invest 2019;129:4875-84. [PMID: 31430261 DOI: 10.1172/JCI128626] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
259 Zhang Y, Shen T, Zhou S, Wang W, Lin S, Zhu G. pH-Responsive STING-Activating DNA Nanovaccines for Cancer Immunotherapy. Adv Ther (Weinh) 2020;3:2000083. [PMID: 34337143 DOI: 10.1002/adtp.202000083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
260 García-Romero N, Palacín-Aliana I, Esteban-Rubio S, Madurga R, Rius-Rocabert S, Carrión-Navarro J, Presa J, Cuadrado-Castano S, Sánchez-Gómez P, García-Sastre A, Nistal-Villan E, Ayuso-Sacido A. Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion. Cells 2020;9:E1405. [PMID: 32516884 DOI: 10.3390/cells9061405] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
261 Swaminathan S, Hansen AS, Heftdal LD, Dhanasekaran R, Deutzmann A, Fernandez WDM, Liefwalker DF, Horton C, Mosley A, Liebersbach M, Maecker HT, Felsher DW. MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies. Nat Commun 2020;11:2860. [PMID: 32503978 DOI: 10.1038/s41467-020-16447-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
262 He C, Huang X, Zhang Y, Lin X, Li S. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. Clin Transl Med 2020;10:e39. [PMID: 32508058 DOI: 10.1002/ctm2.39] [Cited by in Crossref: 8] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
263 Ambrose RL, Brice AM, Caputo AT, Alexander MR, Tribolet L, Liu YC, Adams TE, Bean AGD, Stewart CR. Molecular characterisation of ILRUN, a novel inhibitor of proinflammatory and antimicrobial cytokines. Heliyon 2020;6:e04115. [PMID: 32518853 DOI: 10.1016/j.heliyon.2020.e04115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
264 Heidegger S, Wintges A, Stritzke F, Bek S, Steiger K, Koenig PA, Göttert S, Engleitner T, Öllinger R, Nedelko T, Fischer JC, Makarov V, Winter C, Rad R, van den Brink MRM, Ruland J, Bassermann F, Chan TA, Haas T, Poeck H. RIG-I activation is critical for responsiveness to checkpoint blockade. Sci Immunol 2019;4:eaau8943. [PMID: 31519811 DOI: 10.1126/sciimmunol.aau8943] [Cited by in Crossref: 39] [Cited by in F6Publishing: 45] [Article Influence: 19.5] [Reference Citation Analysis]
265 Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: TLR3 agonists in cancer therapy. Oncoimmunology 2020;9:1771143. [PMID: 32934877 DOI: 10.1080/2162402X.2020.1771143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
266 Zhou L, Hou B, Wang D, Sun F, Song R, Shao Q, Wang H, Yu H, Li Y. Engineering Polymeric Prodrug Nanoplatform for Vaccination Immunotherapy of Cancer. Nano Lett 2020;20:4393-402. [DOI: 10.1021/acs.nanolett.0c01140] [Cited by in Crossref: 22] [Cited by in F6Publishing: 41] [Article Influence: 11.0] [Reference Citation Analysis]
267 Serpico AF, Visconti R, Grieco D. Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment. Cell Death Dis 2020;11:361. [PMID: 32398657 DOI: 10.1038/s41419-020-2567-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
268 Somerville TDD, Xu Y, Wu XS, Maia-Silva D, Hur SK, de Almeida LMN, Preall JB, Koo PK, Vakoc CR. ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer. Proc Natl Acad Sci U S A 2020;117:11471-82. [PMID: 32385160 DOI: 10.1073/pnas.1921484117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
269 Odnokoz O, Yu P, Peck AR, Sun Y, Kovatich AJ, Hooke JA, Hu H, Mitchell EP, Rui H, Fuchs SY. Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers. Cancer Biol Ther 2020;21:629-36. [PMID: 32378445 DOI: 10.1080/15384047.2020.1750297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
270 Aljohani AI, Joseph C, Kurozumi S, Mohammed OJ, Miligy IM, Green AR, Rakha EA. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer. Breast Cancer Res Treat 2020;181:541-51. [PMID: 32350677 DOI: 10.1007/s10549-020-05646-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
271 Gong K, Guo G, Panchani N, Bender ME, Gerber DE, Minna JD, Fattah F, Gao B, Peyton M, Kernstine K, Mukherjee B, Burma S, Chiang CM, Zhang S, Sathe AA, Xing C, Dao KH, Zhao D, Akbay EA, Habib AA. EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nat Cancer 2020;1:394-409. [PMID: 33269343 DOI: 10.1038/s43018-020-0048-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 21] [Article Influence: 6.5] [Reference Citation Analysis]
272 Kitajima S, Li F, Takahashi C. Tumor Milieu Controlled by RB Tumor Suppressor. Int J Mol Sci. 2020;21. [PMID: 32244804 DOI: 10.3390/ijms21072450] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
273 Martin-Hijano L, Sainz B Jr. The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway. Front Immunol 2020;11:526. [PMID: 32296435 DOI: 10.3389/fimmu.2020.00526] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
274 Zhang W, Hu X, Liang J, Zhu Y, Zeng B, Feng L, Zhao C, Liu S, Liu B, Zhang K. oHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity. Mol Ther Oncolytics 2020;16:158-71. [PMID: 32055679 DOI: 10.1016/j.omto.2019.12.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
275 Karimzadeh MR, Zarin M, Ehtesham N, Khosravi S, Soosanabadi M, Mosallaei M, Pourdavoud P. MicroRNA binding site polymorphism in inflammatory genes associated with colorectal cancer: literature review and bioinformatics analysis. Cancer Gene Ther 2020;27:739-53. [PMID: 32203060 DOI: 10.1038/s41417-020-0172-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
276 Ni Q, Zhang F, Liu Y, Wang Z, Yu G, Liang B, Niu G, Su T, Zhu G, Lu G, Zhang L, Chen X. A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Sci Adv. 2020;6:eaaw6071. [PMID: 32206706 DOI: 10.1126/sciadv.aaw6071] [Cited by in Crossref: 33] [Cited by in F6Publishing: 75] [Article Influence: 16.5] [Reference Citation Analysis]
277 Liu Y, Ma J, Yang Y, Liu L, Zhu G, Wang X, Wang S, Guo W, Yue Q, Zhao T, Li C, Gao T, Shi Q. Impact of Interferon-alpha1b (IFN-α1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma. Med Sci Monit 2020;26:e922790. [PMID: 32210221 DOI: 10.12659/MSM.922790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
278 Rehwinkel J, Gack MU. RIG-I-like receptors: their regulation and roles in RNA sensing. Nat Rev Immunol. 2020;20:537-551. [PMID: 32203325 DOI: 10.1038/s41577-020-0288-3] [Cited by in Crossref: 148] [Cited by in F6Publishing: 306] [Article Influence: 74.0] [Reference Citation Analysis]
279 Zhou L, Zhang Y, Wang Y, Zhang M, Sun W, Dai T, Wang A, Wu X, Zhang S, Wang S, Zhou F. A Dual Role of Type I Interferons in Antitumor Immunity. Adv Biosyst 2020;4:e1900237. [PMID: 33245214 DOI: 10.1002/adbi.201900237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
280 Wang Z, Sheng C, Yao C, Chen H, Wang D, Chen S. The EF-Hand Protein CALML6 Suppresses Antiviral Innate Immunity by Impairing IRF3 Dimerization. Cell Rep 2019;26:1273-1285.e5. [PMID: 30699354 DOI: 10.1016/j.celrep.2019.01.030] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
281 Yin P, Li H, Ke C, Cao G, Xin X, Hu J, Cai X, Li L, Liu X, Du B. Intranasal Delivery of Immunotherapeutic Nanoformulations for Treatment of Glioma Through in situ Activation of Immune Response. Int J Nanomedicine 2020;15:1499-515. [PMID: 32189965 DOI: 10.2147/IJN.S240551] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
282 Yang J, Zhang C. Regulation of cancer‐immunity cycle and tumor microenvironment by nanobiomaterials to enhance tumor immunotherapy. WIREs Nanomed Nanobiotechnol 2020;12. [DOI: 10.1002/wnan.1612] [Cited by in Crossref: 4] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
283 Peng D, Chen L, Sun Y, Sun L, Yin Q, Deng S, Niu L, Lou F, Wang Z, Xu Z, Wang C, Fan L, Wang H, Wang H. Melanoma suppression by quercein is correlated with RIG-I and type I interferon signaling. Biomed Pharmacother 2020;125:109984. [PMID: 32066042 DOI: 10.1016/j.biopha.2020.109984] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
284 Busch E, Kubon KD, Mayer JKM, Pidelaserra-Martí G, Albert J, Hoyler B, Heidbuechel JPW, Stephenson KB, Lichty BD, Osen W, Eichmüller SB, Jäger D, Ungerechts G, Engeland CE. Measles Vaccines Designed for Enhanced CD8+ T Cell Activation. Viruses 2020;12:E242. [PMID: 32098134 DOI: 10.3390/v12020242] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
285 Lee AK, Pan D, Bao X, Hu M, Li F, Li CY. Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy. Radiat Res 2020;193:305-17. [PMID: 32074012 DOI: 10.1667/RADE-20-00013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
286 Whelan R, Prince E, Gilani A, Hankinson T. The Inflammatory Milieu of Adamantinomatous Craniopharyngioma and Its Implications for Treatment. J Clin Med 2020;9:E519. [PMID: 32075140 DOI: 10.3390/jcm9020519] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
287 Di Marco T, Bianchi F, Sfondrini L, Todoerti K, Bongarzone I, Maffioli EM, Tedeschi G, Mazzoni M, Pagliardini S, Pellegrini S, Neri A, Anania MC, Greco A. COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death. Cancer Lett 2020;476:106-19. [PMID: 32061953 DOI: 10.1016/j.canlet.2020.02.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
288 Monti M, Consoli F, Vescovi R, Bugatti M, Vermi W. Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma. Cells 2020;9:E417. [PMID: 32054102 DOI: 10.3390/cells9020417] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
289 Zhou Y, Fei M, Zhang G, Liang WC, Lin W, Wu Y, Piskol R, Ridgway J, McNamara E, Huang H, Zhang J, Oh J, Patel JM, Jakubiak D, Lau J, Blackwood B, Bravo DD, Shi Y, Wang J, Hu HM, Lee WP, Jesudason R, Sangaraju D, Modrusan Z, Anderson KR, Warming S, Roose-Girma M, Yan M. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. Immunity 2020;52:357-373.e9. [PMID: 32049051 DOI: 10.1016/j.immuni.2020.01.014] [Cited by in Crossref: 71] [Cited by in F6Publishing: 92] [Article Influence: 35.5] [Reference Citation Analysis]
290 Fu K, Hui B, Wang Q, Lu C, Shi W, Zhang Z, Rong D, Zhang B, Tian Z, Tang W, Cao H, Wang X, Chen Z. Single-cell RNA sequencing of immune cells in gastric cancer patients. Aging (Albany NY) 2020;12:2747-63. [PMID: 32039830 DOI: 10.18632/aging.102774] [Cited by in Crossref: 6] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
291 Cetintas VB, Batada NN. Is there a causal link between PTEN deficient tumors and immunosuppressive tumor microenvironment? J Transl Med 2020;18:45. [PMID: 32000794 DOI: 10.1186/s12967-020-02219-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
292 Rahimi Kalateh Shah Mohammad G, Ghahremanloo A, Soltani A, Fathi E, Hashemy SI. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. J Cell Physiol 2020;235:5449-60. [PMID: 31970790 DOI: 10.1002/jcp.29491] [Cited by in Crossref: 9] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
293 Klepsch V, Pommermayr M, Humer D, Brigo N, Hermann-Kleiter N, Baier G. Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy. Cell Commun Signal 2020;18:8. [PMID: 31937317 DOI: 10.1186/s12964-019-0454-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
294 Silva LC, Fonseca FP, Almeida OP, Mariz BA, Lopes MA, Radhakrishnan R, Sharma M, Kowalski LP, Vargas PA. CD1a+ and CD207+ cells are reduced in oral submucous fibrosis and oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2020;25:e49-55. [PMID: 31880289 DOI: 10.4317/medoral.23177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
295 Egen JG, Ouyang W, Wu LC. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials. Immunity 2020;52:36-54. [DOI: 10.1016/j.immuni.2019.12.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 68] [Article Influence: 22.5] [Reference Citation Analysis]
296 Leong WI, Ames RY, Haverkamp JM, Torres L, Kline J, Bans A, Rocha L, Gallotta M, Guiducci C, Coffman RL, Janatpour MJ. Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses. Oncotarget 2019;10:7220-37. [PMID: 31921384 DOI: 10.18632/oncotarget.27322] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
297 Souliotis VL, Vlachogiannis NI, Pappa M, Argyriou A, Ntouros PA, Sfikakis PP. DNA Damage Response and Oxidative Stress in Systemic Autoimmunity. Int J Mol Sci 2019;21:E55. [PMID: 31861764 DOI: 10.3390/ijms21010055] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 12.0] [Reference Citation Analysis]
298 Gale EC, Roth GA, Smith AAA, Alcántara‐hernández M, Idoyaga J, Appel EA. A Nanoparticle Platform for Improved Potency, Stability, and Adjuvanticity of Poly(I:C). Adv Therap 2020;3:1900174. [DOI: 10.1002/adtp.201900174] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
299 Xi Q, Wang M, Jia W, Yang M, Hu J, Jin J, Chen X, Yin D, Wang X. Design, Synthesis, and Biological Evaluation of Amidobenzimidazole Derivatives as Stimulator of Interferon Genes (STING) Receptor Agonists. J Med Chem 2020;63:260-82. [DOI: 10.1021/acs.jmedchem.9b01567] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
300 Xu P, Ye S, Li K, Huang M, Wang Q, Zeng S, Chen X, Gao W, Chen J, Zhang Q, Zhong Z, Lin Y, Rong Z, Xu Y, Hao B, Peng A, Ouyang M, Liu Q. NOS1 inhibits the interferon response of cancer cells by S-nitrosylation of HDAC2. J Exp Clin Cancer Res 2019;38:483. [PMID: 31805977 DOI: 10.1186/s13046-019-1448-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 28] [Article Influence: 4.3] [Reference Citation Analysis]
301 Saint Fleur-Lominy S, Maus M, Vaeth M, Lange I, Zee I, Suh D, Liu C, Wu X, Tikhonova A, Aifantis I, Feske S. STIM1 and STIM2 Mediate Cancer-Induced Inflammation in T Cell Acute Lymphoblastic Leukemia. Cell Rep 2018;24:3045-3060.e5. [PMID: 30208327 DOI: 10.1016/j.celrep.2018.08.030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
302 Testori AAE, Ribero S, Indini A, Mandalà M. Adjuvant Treatment of Melanoma: Recent Developments and Future Perspectives. Am J Clin Dermatol 2019;20:817-27. [PMID: 31177507 DOI: 10.1007/s40257-019-00456-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
303 Kim SY, Kim S, Kim JE, Lee SN, Shin IW, Shin HS, Jin SM, Noh YW, Kang YJ, Kim YS, Kang TH, Park YM, Lim YT. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy. ACS Nano 2019;13:12671-86. [PMID: 31589013 DOI: 10.1021/acsnano.9b04207] [Cited by in Crossref: 41] [Cited by in F6Publishing: 46] [Article Influence: 13.7] [Reference Citation Analysis]
304 Du B, Waxman DJ. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Cancer Lett 2020;470:170-80. [PMID: 31765733 DOI: 10.1016/j.canlet.2019.11.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 5.3] [Reference Citation Analysis]
305 Bonora M, Wieckowski MR, Sinclair DA, Kroemer G, Pinton P, Galluzzi L. Targeting mitochondria for cardiovascular disorders: therapeutic potential and obstacles. Nat Rev Cardiol 2019;16:33-55. [PMID: 30177752 DOI: 10.1038/s41569-018-0074-0] [Cited by in Crossref: 83] [Cited by in F6Publishing: 99] [Article Influence: 27.7] [Reference Citation Analysis]
306 Yi M, Dong B, Qin S, Chu Q, Wu K, Luo S. Advances and perspectives of PARP inhibitors. Exp Hematol Oncol 2019;8:29. [PMID: 31737426 DOI: 10.1186/s40164-019-0154-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 47] [Article Influence: 9.7] [Reference Citation Analysis]
307 Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov 2019;18:197-218. [PMID: 30610226 DOI: 10.1038/s41573-018-0007-y] [Cited by in Crossref: 655] [Cited by in F6Publishing: 1018] [Article Influence: 218.3] [Reference Citation Analysis]
308 Borden EC. Interferons α and β in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov 2019;18:219-34. [PMID: 30679806 DOI: 10.1038/s41573-018-0011-2] [Cited by in Crossref: 76] [Cited by in F6Publishing: 115] [Article Influence: 25.3] [Reference Citation Analysis]
309 Zheng M, Huang J, Tong A, Yang H. Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances.Mol Ther Oncolytics. 2019;15:234-247. [PMID: 31872046 DOI: 10.1016/j.omto.2019.10.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 82] [Article Influence: 30.7] [Reference Citation Analysis]
310 Xu Q, Rangaswamy US, Wang W, Robbins SH, Harper J, Jin H, Cheng X. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo. Int J Cancer 2020;146:531-41. [PMID: 31584185 DOI: 10.1002/ijc.32694] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
311 Ding J, Zhao D, Hu Y, Liu M, Liao X, Zhao B, Liu X, Deng Y, Song Y. Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy. International Journal of Pharmaceutics 2019;571:118706. [DOI: 10.1016/j.ijpharm.2019.118706] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
312 Young PA, Yamada RE, Trinh KR, Vasuthasawat A, De Oliveira S, Yamada DH, Morrison SL, Timmerman JM. Activity of Anti-CD19 Chimeric Antigen Receptor T Cells Against B Cell Lymphoma Is Enhanced by Antibody-Targeted Interferon-Alpha. J Interferon Cytokine Res 2018;38:239-54. [PMID: 29920129 DOI: 10.1089/jir.2018.0030] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
313 Shahzadi SK, Qadir MA, Mahmood N, Ahmed M. Pegylation and Cell Based Bioassay of Human Interferon-α2b Along its Docking Studies and Effect on Plasma Half-Life. Protein Pept Lett 2020;27:219-24. [PMID: 31612813 DOI: 10.2174/0929866526666191014124026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
314 Su T, Zhang Y, Valerie K, Wang XY, Lin S, Zhu G. STING activation in cancer immunotherapy. Theranostics 2019;9:7759-71. [PMID: 31695799 DOI: 10.7150/thno.37574] [Cited by in Crossref: 86] [Cited by in F6Publishing: 82] [Article Influence: 28.7] [Reference Citation Analysis]
315 Wang C, Beiss V, Steinmetz NF. Cowpea Mosaic Virus Nanoparticles and Empty Virus-Like Particles Show Distinct but Overlapping Immunostimulatory Properties. J Virol 2019;93:e00129-19. [PMID: 31375592 DOI: 10.1128/JVI.00129-19] [Cited by in Crossref: 21] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
316 Nakamura K, Smyth MJ. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment. Cell Mol Immunol 2020;17:1-12. [PMID: 31611651 DOI: 10.1038/s41423-019-0306-1] [Cited by in Crossref: 66] [Cited by in F6Publishing: 102] [Article Influence: 22.0] [Reference Citation Analysis]
317 Jiang X, Muthusamy V, Fedorova O, Kong Y, Kim DJ, Bosenberg M, Pyle AM, Iwasaki A. Intratumoral delivery of RIG-I agonist SLR14 induces robust antitumor responses. J Exp Med 2019;216:2854-68. [PMID: 31601678 DOI: 10.1084/jem.20190801] [Cited by in Crossref: 15] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
318 Kepp O, Marabelle A, Zitvogel L, Kroemer G. Oncolysis without viruses — inducing systemic anticancer immune responses with local therapies. Nat Rev Clin Oncol 2020;17:49-64. [DOI: 10.1038/s41571-019-0272-7] [Cited by in Crossref: 34] [Cited by in F6Publishing: 48] [Article Influence: 11.3] [Reference Citation Analysis]
319 Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature 2019;574:45-56. [PMID: 31578484 DOI: 10.1038/s41586-019-1593-5] [Cited by in Crossref: 166] [Cited by in F6Publishing: 242] [Article Influence: 55.3] [Reference Citation Analysis]
320 Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nano Today 2019;28:100766. [DOI: 10.1016/j.nantod.2019.100766] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 17.7] [Reference Citation Analysis]
321 Wang LA, Yang B, Rao W, Xiao H, Wang D, Jiang J. The correlation of BER protein, IRF3 with CD8+ T cell and their prognostic significance in upper tract urothelial carcinoma. Onco Targets Ther 2019;12:7725-35. [PMID: 31576137 DOI: 10.2147/OTT.S222422] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
322 Tian R, Seim I, Zhang Z, Yang Y, Ren W, Xu S, Yang G. Distinct evolution of toll-like receptor signaling pathway genes in cetaceans. Genes Genomics 2019;41:1417-30. [PMID: 31535317 DOI: 10.1007/s13258-019-00861-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
323 Kim HY, Kim TH, Yoon HK, Lee A. The Role of Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio in Predicting Neoadjuvant Chemotherapy Response in Breast Cancer. J Breast Cancer 2019;22:425-38. [PMID: 31598342 DOI: 10.4048/jbc.2019.22.e41] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
324 Li A, Yi M, Qin S, Chu Q, Luo S, Wu K. Prospects for combining immune checkpoint blockade with PARP inhibition. J Hematol Oncol 2019;12:98. [PMID: 31521196 DOI: 10.1186/s13045-019-0784-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 58] [Article Influence: 14.3] [Reference Citation Analysis]
325 De Vrieze J, Louage B, Deswarte K, Zhong Z, De Coen R, Van Herck S, Nuhn L, Kaas Frich C, Zelikin AN, Lienenklaus S, Sanders NN, Lambrecht BN, David SA, De Geest BG. Potent Lymphatic Translocation and Spatial Control Over Innate Immune Activation by Polymer-Lipid Amphiphile Conjugates of Small-Molecule TLR7/8 Agonists. Angew Chem Int Ed Engl 2019;58:15390-5. [PMID: 31397948 DOI: 10.1002/anie.201905687] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
326 De Vrieze J, Louage B, Deswarte K, Zhong Z, De Coen R, Van Herck S, Nuhn L, Kaas Frich C, Zelikin AN, Lienenklaus S, Sanders NN, Lambrecht BN, David SA, De Geest BG. Amphiphile Polymer‐Lipidkonjugate zur potenten lymphatischen Anreicherung von TLR7/8‐Agonisten ermöglichen eine örtlich begrenzte Aktivierung des angeborenen Immunsystems. Angew Chem 2019;131:15535-41. [DOI: 10.1002/ange.201905687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
327 Verver D, Poirier-Colame V, Tomasic G, Cherif-Rebai K, Grunhagen DJ, Verhoef C, Suciu S, Robert C, Zitvogel L, Eggermont AMM. Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas. Oncoimmunology 2019;8:e1660121. [PMID: 31646109 DOI: 10.1080/2162402X.2019.1660121] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
328 Falahat R, Perez-Villarroel P, Mailloux AW, Zhu G, Pilon-Thomas S, Barber GN, Mulé JJ. STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity. Cancer Immunol Res 2019;7:1837-48. [PMID: 31462408 DOI: 10.1158/2326-6066.CIR-19-0229] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
329 Yang L, Ding JL. MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling. Front Immunol 2019;10:2020. [PMID: 31507609 DOI: 10.3389/fimmu.2019.02020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
330 Mu X, Greenwald E, Ahmad S, Hur S. An origin of the immunogenicity of in vitro transcribed RNA. Nucleic Acids Res 2018;46:5239-49. [PMID: 29534222 DOI: 10.1093/nar/gky177] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 12.7] [Reference Citation Analysis]
331 Wang Z, Guo J, Sun J, Liang P, Wei Y, Deng X, Gao W. Thermoresponsive and Protease-Cleavable Interferon-Polypeptide Conjugates with Spatiotemporally Programmed Two-Step Release Kinetics for Tumor Therapy. Adv Sci (Weinh) 2019;6:1900586. [PMID: 31453069 DOI: 10.1002/advs.201900586] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
332 Baracco EE, Stoll G, Van Endert P, Zitvogel L, Vacchelli E, Kroemer G. Contribution of annexin A1 to anticancer immunosurveillance. Oncoimmunology 2019;8:e1647760. [PMID: 32923172 DOI: 10.1080/2162402X.2019.1647760] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
333 Wang Z, Chen J, Hu J, Zhang H, Xu F, He W, Wang X, Li M, Lu W, Zeng G, Zhou P, Huang P, Chen S, Li W, Xia LP, Xia X. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity. J Clin Invest 2019;129:4850-62. [PMID: 31408442 DOI: 10.1172/JCI127471] [Cited by in Crossref: 39] [Cited by in F6Publishing: 53] [Article Influence: 13.0] [Reference Citation Analysis]
334 Varricchi G, Loffredo S, Marone G, Modestino L, Fallahi P, Ferrari SM, de Paulis A, Antonelli A, Galdiero MR. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition. Int J Mol Sci 2019;20:E3934. [PMID: 31412566 DOI: 10.3390/ijms20163934] [Cited by in Crossref: 29] [Cited by in F6Publishing: 40] [Article Influence: 9.7] [Reference Citation Analysis]
335 Umemoto S, Haruta M, Sakisaka M, Ikeda T, Tsukamoto H, Komohara Y, Takeya M, Nishimura Y, Senju S. Cancer therapy with major histocompatibility complex-deficient and interferon β-producing myeloid cells derived from allogeneic embryonic stem cells. Cancer Sci 2019;110:3027-37. [PMID: 31348591 DOI: 10.1111/cas.14144] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
336 Marchini A, Daeffler L, Pozdeev VI, Angelova A, Rommelaere J. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study.Front Immunol. 2019;10:1848. [PMID: 31440242 DOI: 10.3389/fimmu.2019.01848] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 8.7] [Reference Citation Analysis]
337 Shimizu K, Iyoda T, Okada M, Yamasaki S, Fujii SI. Immune suppression and reversal of the suppressive tumor microenvironment. Int Immunol 2018;30:445-54. [PMID: 29939325 DOI: 10.1093/intimm/dxy042] [Cited by in Crossref: 50] [Cited by in F6Publishing: 61] [Article Influence: 16.7] [Reference Citation Analysis]
338 Hubert M, Gobbini E, Bendriss-Vermare N, Caux C, Valladeau-Guilemond J. Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses. Cancers (Basel) 2019;11:E1082. [PMID: 31366174 DOI: 10.3390/cancers11081082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
339 Durante M, Formenti S. Harnessing radiation to improve immunotherapy: better with particles? Br J Radiol 2020;93:20190224. [PMID: 31317768 DOI: 10.1259/bjr.20190224] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
340 Li X, Liu Z, Zhang A, Han C, Shen A, Jiang L, Boothman DA, Qiao J, Wang Y, Huang X, Fu YX. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nat Commun 2019;10:3251. [PMID: 31324798 DOI: 10.1038/s41467-019-11238-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
341 Kabacaoglu D, Ruess DA, Ai J, Algül H. NF-κB/Rel Transcription Factors in Pancreatic Cancer: Focusing on RelA, c-Rel, and RelB. Cancers (Basel) 2019;11:E937. [PMID: 31277415 DOI: 10.3390/cancers11070937] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
342 Lu C, Klement JD, Ibrahim ML, Xiao W, Redd PS, Nayak-Kapoor A, Zhou G, Liu K. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes. J Immunother Cancer 2019;7:157. [PMID: 31228946 DOI: 10.1186/s40425-019-0635-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 10.7] [Reference Citation Analysis]
343 Zhu C, Zou C, Guan G, Guo Q, Yan Z, Liu T, Shen S, Xu X, Chen C, Lin Z, Cheng W, Wu A. Development and validation of an interferon signature predicting prognosis and treatment response for glioblastoma. Oncoimmunology 2019;8:e1621677. [PMID: 31428519 DOI: 10.1080/2162402X.2019.1621677] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
344 Rozenblit M, Hendrickx W, Heguy A, Chiriboga L, Loomis C, Ray K, Darvishian F, Egeblad M, Demaria S, Marincola FM, Bedognetti D, Adams S. Transcriptomic profiles conducive to immune-mediated tumor rejection in human breast cancer skin metastases treated with Imiquimod. Sci Rep 2019;9:8572. [PMID: 31189943 DOI: 10.1038/s41598-019-42784-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
345 Sosnovtseva AO, Zheltukhin AO, Lipatova AV, Chumakov PM, Chekhonin VP. Oncolytic Activity of the Vaccine Strain of Type 3 Poliovirus on the Model of Rat Glioma C6 Cells. Bull Exp Biol Med 2019;167:111-5. [PMID: 31177454 DOI: 10.1007/s10517-019-04472-6] [Reference Citation Analysis]
346 Zhang W, Wang G, Xu ZG, Tu H, Hu F, Dai J, Chang Y, Chen Y, Lu Y, Zeng H, Cai Z, Han F, Xu C, Jin G, Sun L, Pan BS, Lai SW, Hsu CC, Xu J, Chen ZZ, Li HY, Seth P, Hu J, Zhang X, Li H, Lin HK. Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS. Cell 2019;178:176-189.e15. [PMID: 31155231 DOI: 10.1016/j.cell.2019.05.003] [Cited by in Crossref: 107] [Cited by in F6Publishing: 153] [Article Influence: 35.7] [Reference Citation Analysis]
347 Talebi S, Saeedinia A, Zeinoddini M, Ahmadpour F, Sadeghizadeh M. Evaluation of a single amino acid substitution at position 79 of human IFN-α2b in interferon-receptor assembly and activity. Prep Biochem Biotechnol 2019;49:735-43. [PMID: 31135267 DOI: 10.1080/10826068.2019.1566143] [Reference Citation Analysis]
348 Bego MG, Miguet N, Laliberté A, Aschman N, Gerard F, Merakos AA, Weissenhorn W, Cohen ÉA. Activation of the ILT7 receptor and plasmacytoid dendritic cell responses are governed by structurally-distinct BST2 determinants. J Biol Chem 2019;294:10503-18. [PMID: 31118237 DOI: 10.1074/jbc.RA119.008481] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
349 Zhang Q, Green MD, Lang X, Lazarus J, Parsels JD, Wei S, Parsels LA, Shi J, Ramnath N, Wahl DR, Pasca di Magliano M, Frankel TL, Kryczek I, Lei YL, Lawrence TS, Zou W, Morgan MA. Inhibition of ATM Increases Interferon Signaling and Sensitizes Pancreatic Cancer to Immune Checkpoint Blockade Therapy. Cancer Res 2019;79:3940-51. [PMID: 31101760 DOI: 10.1158/0008-5472.CAN-19-0761] [Cited by in Crossref: 53] [Cited by in F6Publishing: 80] [Article Influence: 17.7] [Reference Citation Analysis]
350 Vascotto F, Petschenka J, Walzer KC, Vormehr M, Brkic M, Strobl S, Rösemann R, Diken M, Kreiter S, Türeci Ö, Sahin U. Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8+ T cell response. Oncoimmunology 2019;8:1601480. [PMID: 31143525 DOI: 10.1080/2162402X.2019.1601480] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
351 Wylie B, Macri C, Mintern JD, Waithman J. Dendritic Cells and Cancer: From Biology to Therapeutic Intervention. Cancers (Basel) 2019;11:E521. [PMID: 30979057 DOI: 10.3390/cancers11040521] [Cited by in Crossref: 39] [Cited by in F6Publishing: 55] [Article Influence: 13.0] [Reference Citation Analysis]
352 Setthawongsin C, Tangkawattana S, Rungsipipat A, Techangamsuwan S. In vitro Effect of Recombinant Feline Interferon-Ω (rFeIFN-Ω) on the Primary CanineTransmissible Venereal Tumor Culture. Front Vet Sci 2019;6:104. [PMID: 31024941 DOI: 10.3389/fvets.2019.00104] [Reference Citation Analysis]
353 Crupi MJF, Bell JC, Singaravelu R. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses. Stem Cells 2019;37:716-23. [PMID: 30875126 DOI: 10.1002/stem.3004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
354 Koucký V, Bouček J, Fialová A. Immunology of Plasmacytoid Dendritic Cells in Solid Tumors: A Brief Review. Cancers (Basel) 2019;11:E470. [PMID: 30987228 DOI: 10.3390/cancers11040470] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 8.3] [Reference Citation Analysis]
355 Rodriguez-ruiz ME, Rodriguez I, Leaman O, López-campos F, Montero A, Conde AJ, Aristu J, Lara P, Calvo FM, Melero I. Immune mechanisms mediating abscopal effects in radioimmunotherapy. Pharmacology & Therapeutics 2019;196:195-203. [DOI: 10.1016/j.pharmthera.2018.12.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
356 Goodman ML, Trinca GM, Walter KR, Papachristou EK, D'Santos CS, Li T, Liu Q, Lai Z, Chalise P, Madan R, Fan F, Markiewicz MA, Jin VX, Carroll JS, Hagan CR. Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer. J Immunol 2019;202:3076-86. [PMID: 30936295 DOI: 10.4049/jimmunol.1801152] [Cited by in Crossref: 13] [Cited by in F6Publishing: 20] [Article Influence: 4.3] [Reference Citation Analysis]
357 Sim CK, Lee JH, Baek IJ, Lee SW, Lee MS. Enhanced Antitumor Immune Response in 2'-5' Oligoadenylate Synthetase-Like 1- (OASL1-) Deficient Mice upon Cisplatin Chemotherapy and Radiotherapy. J Immunol Res 2019;2019:7596786. [PMID: 31049360 DOI: 10.1155/2019/7596786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
358 Wagner F, Hölig U, Wilczkowski F, Plesca I, Sommer U, Wehner R, Kießler M, Jarosch A, Flecke K, Arsova M, Tunger A, Bogner A, Reißfelder C, Weitz J, Schäkel K, Troost EGC, Krause M, Folprecht G, Bornhäuser M, Bachmann MP, Aust D, Baretton G, Schmitz M. Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer. Front Immunol 2019;10:602. [PMID: 30984181 DOI: 10.3389/fimmu.2019.00602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
359 Herheliuk T, Perepelytsina O, Ostapchenko L, Sydorenko M. Effect of Interferon α-2b on Multicellular Tumor Spheroids of MCF-7 Cell Line Enriched with Cancer Stem Cells. Innov Biosyst Bioeng 2019;3:34-44. [DOI: 10.20535/ibb.2019.3.1.157388] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
360 Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, King RL, Niyongere S, Diop MK, Fenaux P, Itzykson R, Willekens C, Ribrag V, Fontenay M, Padron E, Soumelis V, Droin N, Patnaik MM, Solary E. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia 2019;33:2466-80. [PMID: 30894665 DOI: 10.1038/s41375-019-0447-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
361 Salvagno C, Ciampricotti M, Tuit S, Hau CS, van Weverwijk A, Coffelt SB, Kersten K, Vrijland K, Kos K, Ulas T, Song JY, Ooi CH, Rüttinger D, Cassier PA, Jonkers J, Schultze JL, Ries CH, de Visser KE. Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response. Nat Cell Biol 2019;21:511-21. [PMID: 30886344 DOI: 10.1038/s41556-019-0298-1] [Cited by in Crossref: 58] [Cited by in F6Publishing: 71] [Article Influence: 19.3] [Reference Citation Analysis]
362 Bourgeois-Daigneault MC, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, Falls T, St-Germain LE, Pelin A, Lichty BD, Stojdl DF, Ungerechts G, Diallo JS, Bell JC. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018;10:eaao1641. [PMID: 29298865 DOI: 10.1126/scitranslmed.aao1641] [Cited by in Crossref: 129] [Cited by in F6Publishing: 151] [Article Influence: 43.0] [Reference Citation Analysis]
363 Ma Q, Xing C, Long W, Wang HY, Liu Q, Wang RF. Impact of microbiota on central nervous system and neurological diseases: the gut-brain axis. J Neuroinflammation 2019;16:53. [PMID: 30823925 DOI: 10.1186/s12974-019-1434-3] [Cited by in Crossref: 147] [Cited by in F6Publishing: 201] [Article Influence: 49.0] [Reference Citation Analysis]
364 Vulpis E, Soriani A, Cerboni C, Santoni A, Zingoni A. Cancer Exosomes as Conveyors of Stress-Induced Molecules: New Players in the Modulation of NK Cell Response. Int J Mol Sci 2019;20:E611. [PMID: 30708970 DOI: 10.3390/ijms20030611] [Cited by in Crossref: 18] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
365 Macal M, Jo Y, Dallari S, Chang AY, Dai J, Swaminathan S, Wehrens EJ, Fitzgerald-Bocarsly P, Zúñiga EI. Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection. Immunity 2018;48:730-744.e5. [PMID: 29669251 DOI: 10.1016/j.immuni.2018.03.020] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
366 Wang Z, Guo J, Ning J, Feng X, Liu X, Sun J, Chen X, Lu F, Gao W. One-month zero-order sustained release and tumor eradication after a single subcutaneous injection of interferon alpha fused with a body-temperature-responsive polypeptide. Biomater Sci 2019;7:104-12. [DOI: 10.1039/c8bm01096j] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
367 Jacobson ME, Wang-bishop L, Becker KW, Wilson JT. Delivery of 5′-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy. Biomater Sci 2019;7:547-59. [DOI: 10.1039/c8bm01064a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 32] [Article Influence: 7.7] [Reference Citation Analysis]
368 Liu H, Golji J, Brodeur LK, Chung FS, Chen JT, deBeaumont RS, Bullock CP, Jones MD, Kerr G, Li L, Rakiec DP, Schlabach MR, Sovath S, Growney JD, Pagliarini RA, Ruddy DA, MacIsaac KD, Korn JM, McDonald ER 3rd. Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat Med 2019;25:95-102. [PMID: 30559422 DOI: 10.1038/s41591-018-0302-5] [Cited by in Crossref: 100] [Cited by in F6Publishing: 114] [Article Influence: 25.0] [Reference Citation Analysis]
369 Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout SK. Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front Immunol 2018;9:2909. [PMID: 30619273 DOI: 10.3389/fimmu.2018.02909] [Cited by in Crossref: 56] [Cited by in F6Publishing: 97] [Article Influence: 14.0] [Reference Citation Analysis]
370 Tong Y, Zhou L, Yang L, Guo P, Cao Y, Qin FX, Liu J. Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production. EBioMedicine 2019;39:132-44. [PMID: 30528455 DOI: 10.1016/j.ebiom.2018.11.062] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
371 Huber A, Dammeijer F, Aerts JGJV, Vroman H. Current State of Dendritic Cell-Based Immunotherapy: Opportunities for in vitro Antigen Loading of Different DC Subsets? Front Immunol 2018;9:2804. [PMID: 30559743 DOI: 10.3389/fimmu.2018.02804] [Cited by in Crossref: 43] [Cited by in F6Publishing: 64] [Article Influence: 10.8] [Reference Citation Analysis]
372 Merino VF, Cho S, Nguyen N, Sadik H, Narayan A, Talbot C Jr, Cope L, Zhou XC, Zhang Z, Győrffy B, Sukumar S. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. Breast Cancer Res 2018;20:145. [PMID: 30486871 DOI: 10.1186/s13058-018-1068-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
373 Zhao JJ, Zhou ZQ, Wang P, Chen CL, Liu Y, Pan QZ, Zhu Q, Tang Y, Weng DS, Xia JC. Orchestration of immune checkpoints in tumor immune contexture and their prognostic significance in esophageal squamous cell carcinoma. Cancer Manag Res 2018;10:6457-68. [PMID: 30568505 DOI: 10.2147/CMAR.S181949] [Cited by in Crossref: 10] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
374 Ma B, Chen K, Liu P, Li M, Liu J, Sideras K, Sprengers D, Biermann K, Wang W, IJzermans JNM, Cao W, Kwekkeboom J, Peppelenbosch MP, Pan Q. Dichotomal functions of phosphorylated and unphosphorylated STAT1 in hepatocellular carcinoma. J Mol Med (Berl) 2019;97:77-88. [PMID: 30456450 DOI: 10.1007/s00109-018-1717-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
375 Pescarmona R, Belot A, Villard M, Besson L, Lopez J, Mosnier I, Mathieu AL, Lombard C, Garnier L, Frachette C, Walzer T, Viel S. Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies. Cytokine 2019;113:446-52. [PMID: 30413290 DOI: 10.1016/j.cyto.2018.10.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
376 Lybaert L, Vermaelen K, De Geest BG, Nuhn L. Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity. Journal of Controlled Release 2018;289:125-45. [DOI: 10.1016/j.jconrel.2018.09.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
377 Nuhn L, De Koker S, Van Lint S, Zhong Z, Catani JP, Combes F, Deswarte K, Li Y, Lambrecht BN, Lienenklaus S, Sanders NN, David SA, Tavernier J, De Geest BG. Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral Responses. Adv Mater 2018;30:e1803397. [PMID: 30276880 DOI: 10.1002/adma.201803397] [Cited by in Crossref: 73] [Cited by in F6Publishing: 75] [Article Influence: 18.3] [Reference Citation Analysis]
378 Sarhan M, Land WG, Tonnus W, Hugo CP, Linkermann A. Origin and Consequences of Necroinflammation. Physiol Rev 2018;98:727-80. [PMID: 29465288 DOI: 10.1152/physrev.00041.2016] [Cited by in Crossref: 73] [Cited by in F6Publishing: 77] [Article Influence: 18.3] [Reference Citation Analysis]
379 Negishi H, Taniguchi T, Yanai H. The Interferon (IFN) Class of Cytokines and the IFN Regulatory Factor (IRF) Transcription Factor Family. Cold Spring Harb Perspect Biol 2018;10:a028423. [PMID: 28963109 DOI: 10.1101/cshperspect.a028423] [Cited by in Crossref: 60] [Cited by in F6Publishing: 99] [Article Influence: 15.0] [Reference Citation Analysis]
380 Davar D, Wang H, Chauvin JM, Pagliano O, Fourcade JJ, Ka M, Menna C, Rose A, Sander C, Borhani AA, Karunamurthy A, Tarhini AA, Tawbi HA, Zhao Q, Moreno BH, Ebbinghaus S, Ibrahim N, Kirkwood JM, Zarour HM. Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma. J Clin Oncol 2018;:JCO1800632. [PMID: 30359157 DOI: 10.1200/JCO.18.00632] [Cited by in Crossref: 20] [Cited by in F6Publishing: 29] [Article Influence: 5.0] [Reference Citation Analysis]
381 Imamura Y, Tashiro H, Tsend-Ayush G, Haruta M, Dashdemberel N, Komohara Y, Tsuboki J, Takaishi K, Ohba T, Nishimura Y, Katabuchi H, Senju S. Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell-derived myelomonocytic cells producing interferon beta. Cancer Sci 2018;109:3403-10. [PMID: 30142694 DOI: 10.1111/cas.13775] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
382 Zhou H, Mondragón L, Xie W, Mauseth B, Leduc M, Sauvat A, Gomes-da-Silva LC, Forveille S, Iribarren K, Souquere S, Bezu L, Liu P, Zhao L, Zitvogel L, Sveinbjørnsson B, Eksteen JJ, Rekdal Ø, Kepp O, Kroemer G. Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals. Cell Death Dis 2018;9:1086. [PMID: 30352991 DOI: 10.1038/s41419-018-1127-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
383 Au-Yeung N, Horvath CM. Transcriptional and chromatin regulation in interferon and innate antiviral gene expression. Cytokine Growth Factor Rev 2018;44:11-7. [PMID: 30509403 DOI: 10.1016/j.cytogfr.2018.10.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
384 Slim FA, Ouellette G, Ennour-Idrissi K, Jacob S, Diorio C, Durocher F. An isoform of AIF1 involved in breast cancer. Cancer Cell Int 2018;18:167. [PMID: 30386176 DOI: 10.1186/s12935-018-0663-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
385 Kang S, Brown HM, Hwang S. Direct Antiviral Mechanisms of Interferon-Gamma. Immune Netw 2018;18:e33. [PMID: 30402328 DOI: 10.4110/in.2018.18.e33] [Cited by in Crossref: 82] [Cited by in F6Publishing: 93] [Article Influence: 20.5] [Reference Citation Analysis]
386 Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology 2018;7:e1526250. [PMID: 30524908 DOI: 10.1080/2162402X.2018.1526250] [Cited by in Crossref: 90] [Cited by in F6Publishing: 116] [Article Influence: 22.5] [Reference Citation Analysis]
387 Galluzzi L, Yamazaki T, Kroemer G. Linking cellular stress responses to systemic homeostasis. Nat Rev Mol Cell Biol 2018;19:731-45. [DOI: 10.1038/s41580-018-0068-0] [Cited by in Crossref: 146] [Cited by in F6Publishing: 170] [Article Influence: 36.5] [Reference Citation Analysis]
388 Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G. The intracellular signalosome of PD-L1 in cancer cells. Signal Transduct Target Ther 2018;3:26. [PMID: 30275987 DOI: 10.1038/s41392-018-0022-9] [Cited by in Crossref: 87] [Cited by in F6Publishing: 115] [Article Influence: 21.8] [Reference Citation Analysis]
389 Walton RW, Brown MC, Sacco MT, Gromeier M. Engineered Oncolytic Poliovirus PVSRIPO Subverts MDA5-Dependent Innate Immune Responses in Cancer Cells. J Virol 2018;92:e00879-18. [PMID: 29997212 DOI: 10.1128/JVI.00879-18] [Cited by in Crossref: 15] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
390 Strauss BE, Silva GRO, de Luna Vieira I, Cerqueira OLD, Del Valle PR, Medrano RFV, Mendonça SA. Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. Clinics (Sao Paulo) 2018;73:e479s. [PMID: 30208166 DOI: 10.6061/clinics/2018/e479s] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
391 Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology 2018;7:e1511506. [PMID: 30524907 DOI: 10.1080/2162402X.2018.1511506] [Cited by in Crossref: 66] [Cited by in F6Publishing: 84] [Article Influence: 16.5] [Reference Citation Analysis]
392 Jammal MP, Michelin MA, Nomelini RS, Murta EFC. Recombinant poliovirus for cancer immunotherapy. Ann Transl Med 2018;6:368. [PMID: 30370295 DOI: 10.21037/atm.2018.07.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
393 Zhao Y, Schaafsma E, Gorlov IP, Hernando E, Thomas NE, Shen R, Turk MJ, Berwick M, Amos CI, Cheng C. A Leukocyte Infiltration Score Defined by a Gene Signature Predicts Melanoma Patient Prognosis. Mol Cancer Res 2019;17:109-19. [PMID: 30171176 DOI: 10.1158/1541-7786.MCR-18-0173] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
394 van Vloten JP, Workenhe ST, Wootton SK, Mossman KL, Bridle BW. Critical Interactions between Immunogenic Cancer Cell Death, Oncolytic Viruses, and the Immune System Define the Rational Design of Combination Immunotherapies. J Immunol 2018;200:450-8. [PMID: 29311387 DOI: 10.4049/jimmunol.1701021] [Cited by in Crossref: 39] [Cited by in F6Publishing: 46] [Article Influence: 9.8] [Reference Citation Analysis]
395 Gonzalez-Cao M, Karachaliou N, Santarpia M, Viteri S, Meyerhans A, Rosell R. Activation of viral defense signaling in cancer. Ther Adv Med Oncol 2018;10:1758835918793105. [PMID: 30181782 DOI: 10.1177/1758835918793105] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
396 Hou Y, Liang H, Rao E, Zheng W, Huang X, Deng L, Zhang Y, Yu X, Xu M, Mauceri H, Arina A, Weichselbaum RR, Fu YX. Non-canonical NF-κB Antagonizes STING Sensor-Mediated DNA Sensing in Radiotherapy. Immunity 2018;49:490-503.e4. [PMID: 30170810 DOI: 10.1016/j.immuni.2018.07.008] [Cited by in Crossref: 51] [Cited by in F6Publishing: 77] [Article Influence: 12.8] [Reference Citation Analysis]
397 Hiller B, Hoppe A, Haase C, Hiller C, Schubert N, Müller W, Reijns MAM, Jackson AP, Kunkel TA, Wenzel J, Behrendt R, Roers A. Ribonucleotide Excision Repair Is Essential to Prevent Squamous Cell Carcinoma of the Skin. Cancer Res 2018;78:5917-26. [PMID: 30154151 DOI: 10.1158/0008-5472.CAN-18-1099] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
398 Budhwani M, Mazzieri R, Dolcetti R. Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance. Front Oncol 2018;8:322. [PMID: 30186768 DOI: 10.3389/fonc.2018.00322] [Cited by in Crossref: 66] [Cited by in F6Publishing: 87] [Article Influence: 16.5] [Reference Citation Analysis]
399 Du H, Cui S, Li Y, Yang G, Wang P, Fikrig E, You F. MiR-221 negatively regulates innate anti-viral response. PLoS One 2018;13:e0200385. [PMID: 30089112 DOI: 10.1371/journal.pone.0200385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
400 Liu X, Sun M, Sun J, Hu J, Wang Z, Guo J, Gao W. Polymerization Induced Self-Assembly of a Site-Specific Interferon α-Block Copolymer Conjugate into Micelles with Remarkably Enhanced Pharmacology. J Am Chem Soc 2018;140:10435-8. [DOI: 10.1021/jacs.8b06013] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 10.3] [Reference Citation Analysis]
401 Eggermont LJ, Hammink R, Blank KG, Rowan AE, Tel J, Figdor CG. Cytokine-Functionalized Synthetic Dendritic Cells for T Cell Targeted Immunotherapies. Adv Therap 2018;1:1800021. [DOI: 10.1002/adtp.201800021] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
402 Sun J, Yi S, Qiu L, Fu W, Wang A, Liu F, Wang L, Wang T, Chen H, Wang L, Kadin ME, Tu P, Wang Y. SATB1 Defines a Subtype of Cutaneous CD30+ Lymphoproliferative Disorders Associated with a T-Helper 17 Cytokine Profile. Journal of Investigative Dermatology 2018;138:1795-804. [DOI: 10.1016/j.jid.2018.02.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
403 Kimura Y, Negishi H, Matsuda A, Endo N, Hangai S, Inoue A, Nishio J, Taniguchi T, Yanai H. Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways. Cancer Sci 2018;109:2687-96. [PMID: 29981256 DOI: 10.1111/cas.13726] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
404 Su J, Su L, Li D, Shuai O, Zhang Y, Liang H, Jiao C, Xu Z, Lai Y, Xie Y. Antitumor Activity of Extract From the Sporoderm-Breaking Spore of Ganoderma lucidum: Restoration on Exhausted Cytotoxic T Cell With Gut Microbiota Remodeling. Front Immunol 2018;9:1765. [PMID: 30108589 DOI: 10.3389/fimmu.2018.01765] [Cited by in Crossref: 29] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
405 Wong HS, Chang WC. Losses of cytokines and chemokines are common genetic features of human cancers: the somatic copy number alterations are correlated with patient prognoses and therapeutic resistance. Oncoimmunology 2018;7:e1468951. [PMID: 30228934 DOI: 10.1080/2162402X.2018.1468951] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
406 Au-Yeung N, Horvath CM. Histone H2A.Z Suppression of Interferon-Stimulated Transcription and Antiviral Immunity Is Modulated by GCN5 and BRD2. iScience 2018;6:68-82. [PMID: 30240626 DOI: 10.1016/j.isci.2018.07.013] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
407 Amôr NG, de Oliveira CE, Gasparoto TH, Vilas Boas VG, Perri G, Kaneno R, Lara VS, Garlet GP, da Silva JS, Martins GA, Hogaboam C, Cavassani KA, Campanelli AP. ST2/IL-33 signaling promotes malignant development of experimental squamous cell carcinoma by decreasing NK cells cytotoxicity and modulating the intratumoral cell infiltrate. Oncotarget 2018;9:30894-904. [PMID: 30112116 DOI: 10.18632/oncotarget.25768] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
408 Vidyarthi A, Khan N, Agnihotri T, Negi S, Das DK, Aqdas M, Chatterjee D, Colegio OR, Tewari MK, Agrewala JN. TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression. Front Immunol 2018;9:1650. [PMID: 30072995 DOI: 10.3389/fimmu.2018.01650] [Cited by in Crossref: 44] [Cited by in F6Publishing: 55] [Article Influence: 11.0] [Reference Citation Analysis]
409 Ding C, He J, Zhao J, Li J, Chen J, Liao W, Zeng Y, Zhong J, Wei C, Zhang L, Zhou M, Jia Z, Zhang Y, Li H, Zhou Y, Xiao X, Han D, Li C, Zhu Z, Xia Z, Peng J. β-catenin regulates IRF3-mediated innate immune signalling in colorectal cancer. Cell Prolif 2018;51:e12464. [PMID: 30004146 DOI: 10.1111/cpr.12464] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
410 Foote JB, Emens LA. STING signaling: a key to therapeutic tumor immunity. Immunotherapy 2018;10:729-31. [DOI: 10.2217/imt-2018-0064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
411 Vanpouille-Box C, Demaria S, Formenti SC, Galluzzi L. Cytosolic DNA Sensing in Organismal Tumor Control. Cancer Cell 2018;34:361-78. [PMID: 30216189 DOI: 10.1016/j.ccell.2018.05.013] [Cited by in Crossref: 104] [Cited by in F6Publishing: 101] [Article Influence: 26.0] [Reference Citation Analysis]
412 Mitchell D, Chintala S, Dey M. Plasmacytoid dendritic cell in immunity and cancer. J Neuroimmunol 2018;322:63-73. [PMID: 30049538 DOI: 10.1016/j.jneuroim.2018.06.012] [Cited by in Crossref: 36] [Cited by in F6Publishing: 61] [Article Influence: 9.0] [Reference Citation Analysis]
413 Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D. Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus.Oncotarget. 2018;9:28702-28716. [PMID: 29983890 DOI: 10.18632/oncotarget.25614] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
414 Pombo JP, Sanyal S. Perturbation of Intracellular Cholesterol and Fatty Acid Homeostasis During Flavivirus Infections. Front Immunol 2018;9:1276. [PMID: 29915602 DOI: 10.3389/fimmu.2018.01276] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
415 Durante M, Formenti SC. Radiation-Induced Chromosomal Aberrations and Immunotherapy: Micronuclei, Cytosolic DNA, and Interferon-Production Pathway. Front Oncol 2018;8:192. [PMID: 29911071 DOI: 10.3389/fonc.2018.00192] [Cited by in Crossref: 54] [Cited by in F6Publishing: 60] [Article Influence: 13.5] [Reference Citation Analysis]
416 Wennerberg E, Vanpouille-Box C, Bornstein S, Yamazaki T, Demaria S, Galluzzi L. Immune recognition of irradiated cancer cells. Immunol Rev 2017;280:220-30. [PMID: 29027232 DOI: 10.1111/imr.12568] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 9.5] [Reference Citation Analysis]
417 Brown MC, Holl EK, Boczkowski D, Dobrikova E, Mosaheb M, Chandramohan V, Bigner DD, Gromeier M, Nair SK. Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. Sci Transl Med 2017;9:eaan4220. [PMID: 28931654 DOI: 10.1126/scitranslmed.aan4220] [Cited by in Crossref: 101] [Cited by in F6Publishing: 108] [Article Influence: 25.3] [Reference Citation Analysis]
418 Kuwashiro T, Iwane S, Jinghe X, Matsuhashi S, Eguchi Y, Anzai K, Fujimoto K, Mizuta T, Sakamoto N, Ikeda M, Kato N, Ozaki I. Regulation of interferon signaling and HCV‑RNA replication by extracellular matrix. Int J Mol Med 2018;42:957-65. [PMID: 29786754 DOI: 10.3892/ijmm.2018.3693] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
419 Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, Wellbrock C, Llopiz D, Ruiz M, Sarobe P, Breckpot K, Kochan G, Escors D. PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. Cell Rep 2017;20:1818-29. [PMID: 28834746 DOI: 10.1016/j.celrep.2017.07.075] [Cited by in Crossref: 100] [Cited by in F6Publishing: 126] [Article Influence: 25.0] [Reference Citation Analysis]
420 Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, Zhao X, Bellile E, Hu H, Chen H, Polverini PJ, Chen Q, Young S, Carey TE, Nör JE, Ferris RL, Wolf GT, Sun D, Lei YL. Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine. Clin Cancer Res 2018;24:4242-55. [PMID: 29769207 DOI: 10.1158/1078-0432.CCR-17-2807] [Cited by in Crossref: 48] [Cited by in F6Publishing: 60] [Article Influence: 12.0] [Reference Citation Analysis]
421 Xiao W, Klement JD, Lu C, Ibrahim ML, Liu K. IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells. J Immunol 2018;201:264-77. [PMID: 29752314 DOI: 10.4049/jimmunol.1800129] [Cited by in Crossref: 32] [Cited by in F6Publishing: 41] [Article Influence: 8.0] [Reference Citation Analysis]
422 Laengle J, Stift J, Bilecz A, Wolf B, Beer A, Hegedus B, Stremitzer S, Starlinger P, Tamandl D, Pils D, Bergmann M. DNA damage predicts prognosis and treatment response in colorectal liver metastases superior to immunogenic cell death and T cells. Theranostics 2018;8:3198-213. [PMID: 29930723 DOI: 10.7150/thno.24699] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
423 Alsamman K, El-Masry OS. Interferon regulatory factor 1 inactivation in human cancer. Biosci Rep 2018;38:BSR20171672. [PMID: 29599126 DOI: 10.1042/BSR20171672] [Cited by in Crossref: 25] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
424 Bello-Rivero I, Garcia-Vega Y, Duncan-Roberts Y, Vazquez-Blomquistc D, Santana-Milian H, Besada-Perez V, Rios-Cabrera M. HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment. Semin Oncol 2018;45:27-33. [PMID: 30318081 DOI: 10.1053/j.seminoncol.2018.04.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
425 Ahn J, Xia T, Rabasa Capote A, Betancourt D, Barber GN. Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells. Cancer Cell 2018;33:862-873.e5. [PMID: 29706455 DOI: 10.1016/j.ccell.2018.03.027] [Cited by in Crossref: 60] [Cited by in F6Publishing: 81] [Article Influence: 15.0] [Reference Citation Analysis]
426 Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS. Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy. EBioMedicine 2018;31:17-24. [PMID: 29724655 DOI: 10.1016/j.ebiom.2018.04.020] [Cited by in Crossref: 61] [Cited by in F6Publishing: 62] [Article Influence: 15.3] [Reference Citation Analysis]
427 Parisien JP, Lenoir JJ, Mandhana R, Rodriguez KR, Qian K, Bruns AM, Horvath CM. RNA sensor LGP2 inhibits TRAF ubiquitin ligase to negatively regulate innate immune signaling. EMBO Rep 2018;19:e45176. [PMID: 29661858 DOI: 10.15252/embr.201745176] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
428 Yoshida S, Shime H, Takeda Y, Nam JM, Takashima K, Matsumoto M, Shirato H, Kasahara M, Seya T. Toll-like receptor 3 signal augments radiation-induced tumor growth retardation in a murine model. Cancer Sci 2018;109:956-65. [PMID: 29465830 DOI: 10.1111/cas.13543] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
429 Karki R, Lee E, Place D, Samir P, Mavuluri J, Sharma BR, Balakrishnan A, Malireddi RKS, Geiger R, Zhu Q, Neale G, Kanneganti TD. IRF8 Regulates Transcription of Naips for NLRC4 Inflammasome Activation. Cell 2018;173:920-933.e13. [PMID: 29576451 DOI: 10.1016/j.cell.2018.02.055] [Cited by in Crossref: 78] [Cited by in F6Publishing: 93] [Article Influence: 19.5] [Reference Citation Analysis]
430 Nuhn L, Van Hoecke L, Deswarte K, Schepens B, Li Y, Lambrecht BN, De Koker S, David SA, Saelens X, De Geest BG. Potent anti-viral vaccine adjuvant based on pH-degradable nanogels with covalently linked small molecule imidazoquinoline TLR7/8 agonist. Biomaterials 2018;178:643-51. [PMID: 29573820 DOI: 10.1016/j.biomaterials.2018.03.026] [Cited by in Crossref: 33] [Cited by in F6Publishing: 38] [Article Influence: 8.3] [Reference Citation Analysis]
431 Gujar S, Pol JG, Kroemer G. Heating it up: Oncolytic viruses make tumors 'hot' and suitable for checkpoint blockade immunotherapies. Oncoimmunology 2018;7:e1442169. [PMID: 30221036 DOI: 10.1080/2162402X.2018.1442169] [Cited by in Crossref: 35] [Cited by in F6Publishing: 44] [Article Influence: 8.8] [Reference Citation Analysis]
432 Dredge K, Brennan TV, Hammond E, Lickliter JD, Lin L, Bampton D, Handley P, Lankesheer F, Morrish G, Yang Y, Brown MP, Millward M. A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours. Br J Cancer 2018;118:1035-41. [PMID: 29531325 DOI: 10.1038/s41416-018-0006-0] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
433 Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest 2018;128:1413-28. [PMID: 29504948 DOI: 10.1172/JCI98047] [Cited by in Crossref: 59] [Cited by in F6Publishing: 75] [Article Influence: 14.8] [Reference Citation Analysis]
434 Bagaev A, Pichugin A, Nelson EL, Agadjanyan MG, Ghochikyan A, Ataullakhanov RI. Anticancer Mechanisms in Two Murine Bone Marrow-Derived Dendritic Cell Subsets Activated with TLR4 Agonists. J Immunol 2018;200:2656-69. [PMID: 29500244 DOI: 10.4049/jimmunol.1701126] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
435 Pock HL, Wei Bryan TY, Hoon TP, Iqbal J, Ching LY, Tee GY, Wai TK, Chong TH, Wee OK, Wei YK. Standing in the GAP : To formulate a novel radioimmunotherapy regime to improve the long-term outcome in breast cancer. Immunotherapy 2018;10:255-63. [DOI: 10.2217/imt-2017-0080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
436 Cheong JE, Sun L. Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities. Trends in Pharmacological Sciences 2018;39:307-25. [DOI: 10.1016/j.tips.2017.11.007] [Cited by in Crossref: 126] [Cited by in F6Publishing: 162] [Article Influence: 31.5] [Reference Citation Analysis]
437 Vasquez M, Paredes-Cervantes V, Aranda F, Ardaiz N, Gomar C, Berraondo P. Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model. Oncotarget 2017;8:5247-55. [PMID: 28029653 DOI: 10.18632/oncotarget.14127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
438 Lasfar A, de laTorre A, Abushahba W, Cohen-Solal KA, Castaneda I, Yuan Y, Reuhl K, Zloza A, Raveche E, Laskin DL, Kotenko SV. Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth. Oncotarget 2016;7:49259-67. [PMID: 27363032 DOI: 10.18632/oncotarget.10272] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
439 Holl EK, Brown MC, Boczkowski D, McNamara MA, George DJ, Bigner DD, Gromeier M, Nair SK. Recombinant oncolytic poliovirus, PVSRIPO, has potent cytotoxic and innate inflammatory effects, mediating therapy in human breast and prostate cancer xenograft models. Oncotarget 2016;7:79828-41. [PMID: 27806313 DOI: 10.18632/oncotarget.12975] [Cited by in Crossref: 21] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
440 García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology 2018;7:e1433982. [PMID: 29872569 DOI: 10.1080/2162402X.2018.1433982] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 6.3] [Reference Citation Analysis]
441 Kuss-Duerkop SK, Westrich JA, Pyeon D. DNA Tumor Virus Regulation of Host DNA Methylation and Its Implications for Immune Evasion and Oncogenesis. Viruses 2018;10:E82. [PMID: 29438328 DOI: 10.3390/v10020082] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
442 Liu Y, Lv J, Liu J, Liang X, Jin X, Xie J, Zhang L, Chen D, Fiskesund R, Tang K, Ma J, Zhang H, Dong W, Mo S, Zhang T, Cheng F, Zhou Y, Jia Q, Zhu B, Kong Y, Guo J, Zhang H, Hu ZW, Cao X, Qin FX, Huang B. STAT3/p53 pathway activation disrupts IFN-β-induced dormancy in tumor-repopulating cells. J Clin Invest 2018;128:1057-73. [PMID: 29431732 DOI: 10.1172/JCI96329] [Cited by in Crossref: 44] [Cited by in F6Publishing: 57] [Article Influence: 11.0] [Reference Citation Analysis]
443 Pearson FE, Chang K, Minoda Y, Rojas IML, Haigh OL, Daraj G, Tullett KM, Radford KJ. Activation of human CD141+ and CD1c+ dendritic cells in vivo with combined TLR3 and TLR7/8 ligation. Immunol Cell Biol 2018;96:390-400. [PMID: 29344995 DOI: 10.1111/imcb.12009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 5.5] [Reference Citation Analysis]
444 Laghari ZA, Chen SN, Li L, Huang B, Gan Z, Zhou Y, Huo HJ, Hou J, Nie P. Functional, signalling and transcriptional differences of three distinct type I IFNs in a perciform fish, the mandarin fish Siniperca chuatsi. Dev Comp Immunol 2018;84:94-108. [PMID: 29432791 DOI: 10.1016/j.dci.2018.02.008] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 6.3] [Reference Citation Analysis]
445 Schleicher U, Liese J, Justies N, Mischke T, Haeberlein S, Sebald H, Kalinke U, Weiss S, Bogdan C. Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of Leishmania major, but Not for Spontaneous Cure of Subcutaneous Primary or Secondary L. major Infection. Front Immunol 2018;9:79. [PMID: 29459858 DOI: 10.3389/fimmu.2018.00079] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
446 Tarbell KV, Egen JG. Breaking self-tolerance during autoimmunity and cancer immunity: Myeloid cells and type I IFN response regulation. J Leukoc Biol 2018;103:1117-29. [DOI: 10.1002/jlb.3mir1017-400r] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
447 Galluzzi L, Vitale I, Aaronson SA, Abrams JM, Adam D, Agostinis P, Alnemri ES, Altucci L, Amelio I, Andrews DW. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ. 2018;25:486-541. [PMID: 29362479 DOI: 10.1038/s41418-017-0012-4] [Cited by in Crossref: 1577] [Cited by in F6Publishing: 2080] [Article Influence: 394.3] [Reference Citation Analysis]
448 Arimoto K, Miyauchi S, Stoner SA, Fan J, Zhang D. Negative regulation of type I IFN signaling. J Leukoc Biol 2018;103:1099-116. [DOI: 10.1002/jlb.2mir0817-342r] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 10.8] [Reference Citation Analysis]
449 Taniguchi K, Karin M. NF-κB, inflammation, immunity and cancer: coming of age. Nat Rev Immunol 2018;18:309-24. [DOI: 10.1038/nri.2017.142] [Cited by in Crossref: 718] [Cited by in F6Publishing: 1003] [Article Influence: 179.5] [Reference Citation Analysis]
450 Graffeo CS, Perry A, Link MJ, Daniels DJ. Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon. J Neurol Surg B Skull Base 2018;79:65-80. [PMID: 29404243 DOI: 10.1055/s-0037-1621738] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
451 Palmer CR, Jacobson ME, Fedorova O, Pyle AM, Wilson JT. Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs. Bioconjug Chem 2018;29:742-7. [PMID: 29350913 DOI: 10.1021/acs.bioconjchem.7b00697] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
452 Hossain DMS, Javaid S, Cai M, Zhang C, Sawant A, Hinton M, Sathe M, Grein J, Blumenschein W, Pinheiro EM, Chackerian A. Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression. J Clin Invest 2018;128:644-54. [PMID: 29337311 DOI: 10.1172/JCI94586] [Cited by in Crossref: 51] [Cited by in F6Publishing: 64] [Article Influence: 12.8] [Reference Citation Analysis]
453 Marsili G, Perrotti E, Remoli AL, Acchioni C, Sgarbanti M, Battistini A. IFN Regulatory Factors and Antiviral Innate Immunity: How Viruses Can Get Better. J Interferon Cytokine Res 2016;36:414-32. [PMID: 27379864 DOI: 10.1089/jir.2016.0002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
454 Wieser V, Adolph TE, Grander C, Grabherr F, Enrich B, Moser P, Moschen AR, Kaser S, Tilg H. Adipose type I interferon signalling protects against metabolic dysfunction. Gut 2018;67:157-65. [PMID: 28011892 DOI: 10.1136/gutjnl-2016-313155] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
455 Shuvalov O, Kizenko A, Shakirova A, Fedorova O, Petukhov A, Aksenov N, Vasileva E, Daks A, Barlev N. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner. Biochemical and Biophysical Research Communications 2018;495:1233-9. [DOI: 10.1016/j.bbrc.2017.11.118] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
456 Bakrania AK, Variya BC, Rathod LV, Patel SS. DEAE-Dextran coated paclitaxel nanoparticles act as multifunctional nano system for intranuclear delivery to triple negative breast cancer through VEGF and NOTCH1 inhibition. European Journal of Pharmaceutics and Biopharmaceutics 2018;122:37-48. [DOI: 10.1016/j.ejpb.2017.10.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
457 Gujar S, Pol JG, Kim Y, Lee PW, Kroemer G. Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. Trends Immunol 2018;39:209-21. [PMID: 29275092 DOI: 10.1016/j.it.2017.11.006] [Cited by in Crossref: 76] [Cited by in F6Publishing: 83] [Article Influence: 15.2] [Reference Citation Analysis]
458 Nie Z, Aboulnasr F, Natesampillai S, Burke SP, Krogman A, Bren GD, Chung TDY, Anderson JR, Smart MK, Katzmann DJ, Rajagopalan G, Cummins NW, Badley AD. Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment. J Immunol 2018;200:1110-23. [PMID: 29263214 DOI: 10.4049/jimmunol.1701113] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
459 Lhuillier C, Vanpouille-Box C, Galluzzi L, Formenti SC, Demaria S. Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers. Semin Cancer Biol 2018;52:125-34. [PMID: 29258856 DOI: 10.1016/j.semcancer.2017.12.007] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
460 Chae YK, Anker JF, Bais P, Namburi S, Giles FJ, Chuang JH. Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget 2018;9:7949-60. [PMID: 29487705 DOI: 10.18632/oncotarget.23742] [Cited by in Crossref: 36] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
461 Lu R, Turan T, Samayoa J, Marincola FM. Cancer immune resistance: can theories converge? Emerg Top Life Sci 2017;1:411-9. [PMID: 33525800 DOI: 10.1042/ETLS20170060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 2.2] [Reference Citation Analysis]
462 Marincola FM, Demaria S, Vanpouille-box C. TREX1 is a checkpoint for innate immune sensing of DNA damage that fosters cancer immune resistance. Emerging Topics in Life Sciences 2017;1:509-15. [DOI: 10.1042/etls20170063] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
463 Mehla K, Tremayne J, Grunkemeyer JA, O'Connell KA, Steele MM, Caffrey TC, Zhu X, Yu F, Singh PK, Schultes BC, Madiyalakan R, Nicodemus CF, Hollingsworth MA. Combination of mAb-AR20.5, anti-PD-L1 and PolyICLC inhibits tumor progression and prolongs survival of MUC1.Tg mice challenged with pancreatic tumors. Cancer Immunol Immunother 2018;67:445-57. [PMID: 29204701 DOI: 10.1007/s00262-017-2095-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
464 Champion M, Brennan K, Croonenborghs T, Gentles AJ, Pochet N, Gevaert O. Module Analysis Captures Pancancer Genetically and Epigenetically Deregulated Cancer Driver Genes for Smoking and Antiviral Response. EBioMedicine 2018;27:156-66. [PMID: 29331675 DOI: 10.1016/j.ebiom.2017.11.028] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
465 Tarasova IA, Tereshkova AV, Lobas AA, Solovyeva EM, Sidorenko AS, Gorshkov V, Kjeldsen F, Bubis JA, Ivanov MV, Ilina IY, Moshkovskii SA, Chumakov PM, Gorshkov MV. Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. Oncotarget 2018;9:1785-802. [PMID: 29416731 DOI: 10.18632/oncotarget.22751] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
466 Cauwels A, Van Lint S, Garcin G, Bultinck J, Paul F, Gerlo S, Van der Heyden J, Bordat Y, Catteeuw D, De Cauwer L, Rogge E, Verhee A, Uzé G, Tavernier J. A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment. Oncoimmunology 2018;7:e1398876. [PMID: 29399401 DOI: 10.1080/2162402X.2017.1398876] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
467 Igbe I, Shen XF, Jiao W, Qiang Z, Deng T, Li S, Liu WL, Liu HW, Zhang GL, Wang F. Dietary quercetin potentiates the antiproliferative effect of interferon-α in hepatocellular carcinoma cells through activation of JAK/STAT pathway signaling by inhibition of SHP2 phosphatase. Oncotarget 2017;8:113734-48. [PMID: 29371942 DOI: 10.18632/oncotarget.22556] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
468 Chen YA, Shen YL, Hsia HY, Tiang YP, Sung TL, Chen LY. Extrachromosomal telomere repeat DNA is linked to ALT development via cGAS-STING DNA sensing pathway. Nat Struct Mol Biol 2017;24:1124-31. [PMID: 29106411 DOI: 10.1038/nsmb.3498] [Cited by in Crossref: 57] [Cited by in F6Publishing: 64] [Article Influence: 11.4] [Reference Citation Analysis]
469 Ilangumaran S, Williams BRG, Kalvakolanu DV. Meeting summary: 2nd Aegean Conference on Cytokine Signaling in Cancer. Cytokine 2018;108:225-31. [PMID: 29102683 DOI: 10.1016/j.cyto.2017.10.025] [Reference Citation Analysis]
470 Wang L, Ning S. "Toll-free" pathways for production of type I interferons. AIMS Allergy Immunol 2017;1:143-63. [PMID: 29202128 DOI: 10.3934/Allergy.2017.3.143] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
471 Nishimura CD, Brenner DA, Mukherjee M, Hirsch RA, Ott L, Wu MF, Liu H, Dakhova O, Orange JS, Brenner MK, Lin CY, Arber C. c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals. Blood 2017;130:2739-49. [PMID: 29079582 DOI: 10.1182/blood-2017-02-769463] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
472 Donninelli G, Sanseverino I, Purificato C, Gessani S, Gauzzi MC. Dual requirement for STAT signaling in dendritic cell immunobiology. Immunobiology 2018;223:342-7. [PMID: 29092744 DOI: 10.1016/j.imbio.2017.10.049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
473 Lulli D, Carbone ML, Pastore S. The MEK Inhibitors Trametinib and Cobimetinib Induce a Type I Interferon Response in Human Keratinocytes. Int J Mol Sci 2017;18:E2227. [PMID: 29064427 DOI: 10.3390/ijms18102227] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.6] [Reference Citation Analysis]
474 Seelige R, Searles S, Bui JD. Innate sensing of cancer's non-immunologic hallmarks. Curr Opin Immunol 2018;50:1-8. [PMID: 29032295 DOI: 10.1016/j.coi.2017.09.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
475 Wonganan O, He YJ, Shen XF, Wongkrajang K, Suksamrarn A, Zhang GL, Wang F. 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon α/β by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells. Toxicol Appl Pharmacol 2017;336:31-9. [PMID: 29031523 DOI: 10.1016/j.taap.2017.10.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
476 Yang R, Hung M. The role of T-cell immunoglobulin mucin-3 and its ligand galectin-9 in antitumor immunity and cancer immunotherapy. Sci China Life Sci 2017;60:1058-64. [DOI: 10.1007/s11427-017-9176-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
477 Kumari P, Saha I, Narayanan A, Narayanan S, Takaoka A, Kumar NS, Tailor P, Kumar H. Essential role of HCMV deubiquitinase in promoting oncogenesis by targeting anti-viral innate immune signaling pathways. Cell Death Dis 2017;8:e3078. [PMID: 28981114 DOI: 10.1038/cddis.2017.461] [Cited by in Crossref: 24] [Cited by in F6Publishing: 31] [Article Influence: 4.8] [Reference Citation Analysis]
478 Fang R, Wang C, Jiang Q, Lv M, Gao P, Yu X, Mu P, Zhang R, Bi S, Feng JM, Jiang Z. NEMO-IKKβ Are Essential for IRF3 and NF-κB Activation in the cGAS-STING Pathway. J Immunol 2017;199:3222-33. [PMID: 28939760 DOI: 10.4049/jimmunol.1700699] [Cited by in Crossref: 81] [Cited by in F6Publishing: 96] [Article Influence: 16.2] [Reference Citation Analysis]
479 Sato-Kaneko F, Yao S, Ahmadi A, Zhang SS, Hosoya T, Kaneda MM, Varner JA, Pu M, Messer KS, Guiducci C, Coffman RL, Kitaura K, Matsutani T, Suzuki R, Carson DA, Hayashi T, Cohen EE. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight 2017;2:93397. [PMID: 28931759 DOI: 10.1172/jci.insight.93397] [Cited by in Crossref: 120] [Cited by in F6Publishing: 131] [Article Influence: 24.0] [Reference Citation Analysis]
480 Wu D, Sanin DE, Everts B, Chen Q, Qiu J, Buck MD, Patterson A, Smith AM, Chang CH, Liu Z, Artyomov MN, Pearce EL, Cella M, Pearce EJ. Type 1 Interferons Induce Changes in Core Metabolism that Are Critical for Immune Function. Immunity 2016;44:1325-36. [PMID: 27332732 DOI: 10.1016/j.immuni.2016.06.006] [Cited by in Crossref: 138] [Cited by in F6Publishing: 160] [Article Influence: 27.6] [Reference Citation Analysis]
481 Bai Y, Tong Y, Liu Y, Hu H. Self-dsDNA in the pathogenesis of systemic lupus erythematosus. Clin Exp Immunol 2018;191:1-10. [PMID: 28836661 DOI: 10.1111/cei.13041] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 9.0] [Reference Citation Analysis]
482 Newby BN, Mathews CE. Type I Interferon Is a Catastrophic Feature of the Diabetic Islet Microenvironment. Front Endocrinol (Lausanne) 2017;8:232. [PMID: 28959234 DOI: 10.3389/fendo.2017.00232] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
483 Ahmed D, Cassol E. Role of cellular metabolism in regulating type I interferon responses: Implications for tumour immunology and treatment. Cancer Lett 2017;409:20-9. [PMID: 28888999 DOI: 10.1016/j.canlet.2017.08.037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
484 Vanpouille-Box C, Lhuillier C, Bezu L, Aranda F, Yamazaki T, Kepp O, Fucikova J, Spisek R, Demaria S, Formenti SC, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immune checkpoint blockers for cancer therapy. Oncoimmunology 2017;6:e1373237. [PMID: 29147629 DOI: 10.1080/2162402X.2017.1373237] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
485 Cabo M, Offringa R, Zitvogel L, Kroemer G, Muntasell A, Galluzzi L. Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications. Oncoimmunology 2017;6:e1371896. [PMID: 29209572 DOI: 10.1080/2162402X.2017.1371896] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
486 Kim DS, Dastidar H, Zhang C, Zemp FJ, Lau K, Ernst M, Rakic A, Sikdar S, Rajwani J, Naumenko V, Balce DR, Ewanchuk BW, Tailor P, Yates RM, Jenne C, Gafuik C, Mahoney DJ. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms. Nat Commun 2017;8:344. [PMID: 28839138 DOI: 10.1038/s41467-017-00324-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 6.8] [Reference Citation Analysis]
487 Ng KW, Marshall EA, Bell JC, Lam WL. cGAS-STING and Cancer: Dichotomous Roles in Tumor Immunity and Development. Trends Immunol. 2018;39:44-54. [PMID: 28830732 DOI: 10.1016/j.it.2017.07.013] [Cited by in Crossref: 98] [Cited by in F6Publishing: 108] [Article Influence: 19.6] [Reference Citation Analysis]
488 Sood V, Sharma KB, Gupta V, Saha D, Dhapola P, Sharma M, Sen U, Kitajima S, Chowdhury S, Kalia M, Vrati S. ATF3 negatively regulates cellular antiviral signaling and autophagy in the absence of type I interferons. Sci Rep 2017;7:8789. [PMID: 28821775 DOI: 10.1038/s41598-017-08584-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
489 Olesch C, Ringel C, Brüne B, Weigert A. Beyond Immune Cell Migration: The Emerging Role of the Sphingosine-1-phosphate Receptor S1PR4 as a Modulator of Innate Immune Cell Activation. Mediators Inflamm 2017;2017:6059203. [PMID: 28848247 DOI: 10.1155/2017/6059203] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
490 López-soto A, Gonzalez S, Smyth MJ, Galluzzi L. Control of Metastasis by NK Cells. Cancer Cell 2017;32:135-54. [DOI: 10.1016/j.ccell.2017.06.009] [Cited by in Crossref: 278] [Cited by in F6Publishing: 317] [Article Influence: 55.6] [Reference Citation Analysis]
491 Yamazaki T, Galluzzi L. Blinatumomab bridges the gap between leukemia and immunity. Oncoimmunology 2017;6:e1358335. [PMID: 29147620 DOI: 10.1080/2162402X.2017.1358335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
492 Hope C, Emmerich PB, Papadas A, Pagenkopf A, Matkowskyj KA, Van De Hey DR, Payne SN, Clipson L, Callander NS, Hematti P, Miyamoto S, Johnson MG, Deming DA, Asimakopoulos F. Versican-Derived Matrikines Regulate Batf3-Dendritic Cell Differentiation and Promote T Cell Infiltration in Colorectal Cancer. J Immunol 2017;199:1933-41. [PMID: 28754680 DOI: 10.4049/jimmunol.1700529] [Cited by in Crossref: 46] [Cited by in F6Publishing: 53] [Article Influence: 9.2] [Reference Citation Analysis]
493 Vanpouille-Box C, Formenti SC, Demaria S. Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers. Clin Cancer Res 2018;24:259-65. [PMID: 28751442 DOI: 10.1158/1078-0432.CCR-16-0037] [Cited by in Crossref: 84] [Cited by in F6Publishing: 105] [Article Influence: 16.8] [Reference Citation Analysis]
494 Medrano RFV, Hunger A, Mendonça SA, Barbuto JAM, Strauss BE. Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget 2017;8:71249-84. [PMID: 29050360 DOI: 10.18632/oncotarget.19531] [Cited by in Crossref: 78] [Cited by in F6Publishing: 83] [Article Influence: 15.6] [Reference Citation Analysis]
495 Ma H, Jin S, Yang W, Tian Z, Liu S, Wang Y, Zhou G, Zhao M, Gvetadze S, Zhang Z, Hu J. Interferon-α Promotes the Expression of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma. J Cancer 2017;8:2384-93. [PMID: 28819442 DOI: 10.7150/jca.19486] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
496 Pellicioli ACA, Bingle L, Farthing P, Lopes MA, Martins MD, Vargas PA. Immunosurveillance profile of oral squamous cell carcinoma and oral epithelial dysplasia through dendritic and T-cell analysis. J Oral Pathol Med 2017;46:928-33. [PMID: 28585308 DOI: 10.1111/jop.12597] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
497 Araya RE, Goldszmid RS. IFNAR1 Degradation: A New Mechanism for Tumor Immune Evasion? Cancer Cell 2017;31:161-3. [PMID: 28196588 DOI: 10.1016/j.ccell.2017.01.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
498 Bracci L, Sistigu A, Proietti E, Moschella F. The added value of type I interferons to cytotoxic treatments of cancer. Cytokine Growth Factor Rev 2017;36:89-97. [PMID: 28693974 DOI: 10.1016/j.cytogfr.2017.06.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
499 Ayub SG, Kaul D. miR-2909 regulates ISGylation system via STAT1 signalling through negative regulation of SOCS3 in prostate cancer. Andrology 2017;5:790-7. [DOI: 10.1111/andr.12374] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
500 Katlinski KV, Gui J, Katlinskaya YV, Ortiz A, Chakraborty R, Bhattacharya S, Carbone CJ, Beiting DP, Girondo MA, Peck AR, Puré E, Chatterji P, Rustgi AK, Diehl JA, Koumenis C, Rui H, Fuchs SY. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell 2017;31:194-207. [PMID: 28196594 DOI: 10.1016/j.ccell.2017.01.004] [Cited by in Crossref: 106] [Cited by in F6Publishing: 119] [Article Influence: 21.2] [Reference Citation Analysis]
501 Gardner A, Ruffell B. Reducing interferon'ce in stem cells. Nat Cell Biol 2017;19:597-9. [PMID: 28561058 DOI: 10.1038/ncb3544] [Reference Citation Analysis]
502 Snell LM, McGaha TL, Brooks DG. Type I Interferon in Chronic Virus Infection and Cancer. Trends Immunol 2017;38:542-57. [PMID: 28579323 DOI: 10.1016/j.it.2017.05.005] [Cited by in Crossref: 167] [Cited by in F6Publishing: 192] [Article Influence: 33.4] [Reference Citation Analysis]
503 Liao J, Luan Y, Ren Z, Liu X, Xue D, Xu H, Sun Z, Yang K, Peng H, Fu YX. Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression. Cancer Immunol Res 2017;5:560-70. [PMID: 28533311 DOI: 10.1158/2326-6066.CIR-16-0221] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
504 Celià-Terrassa T, Liu DD, Choudhury A, Hang X, Wei Y, Zamalloa J, Alfaro-Aco R, Chakrabarti R, Jiang YZ, Koh BI, Smith HA, DeCoste C, Li JJ, Shao ZM, Kang Y. Normal and cancerous mammary stem cells evade interferon-induced constraint through the miR-199a-LCOR axis. Nat Cell Biol 2017;19:711-23. [PMID: 28530657 DOI: 10.1038/ncb3533] [Cited by in Crossref: 53] [Cited by in F6Publishing: 61] [Article Influence: 10.6] [Reference Citation Analysis]
505 Zhao B, Bhattacharya S, Yu Q, Fuchs SY. Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia. Leuk Lymphoma 2018;59:171-7. [PMID: 28503979 DOI: 10.1080/10428194.2017.1319053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
506 Dunn J, Rao S. Epigenetics and immunotherapy: The current state of play. Mol Immunol 2017;87:227-39. [PMID: 28511092 DOI: 10.1016/j.molimm.2017.04.012] [Cited by in Crossref: 113] [Cited by in F6Publishing: 116] [Article Influence: 22.6] [Reference Citation Analysis]
507 Hanoteau A, Henin C, Svec D, Bisilliat Donnet C, Denanglaire S, Colau D, Romero P, Leo O, Van den Eynde B, Moser M. Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+ T cells. Oncoimmunology 2017;6:e1318234. [PMID: 28919989 DOI: 10.1080/2162402X.2017.1318234] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
508 Snyder DT, Hedges JF, Jutila MA. Getting "Inside" Type I IFNs: Type I IFNs in Intracellular Bacterial Infections. J Immunol Res 2017;2017:9361802. [PMID: 28529959 DOI: 10.1155/2017/9361802] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
509 Parlato S, De Ninno A, Molfetta R, Toschi E, Salerno D, Mencattini A, Romagnoli G, Fragale A, Roccazzello L, Buoncervello M, Canini I, Bentivegna E, Falchi M, Bertani FR, Gerardino A, Martinelli E, Natale C, Paolini R, Businaro L, Gabriele L. 3D Microfluidic model for evaluating immunotherapy efficacy by tracking dendritic cell behaviour toward tumor cells. Sci Rep 2017;7:1093. [PMID: 28439087 DOI: 10.1038/s41598-017-01013-x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 16.2] [Reference Citation Analysis]
510 Luo M, Wang H, Wang Z, Cai H, Lu Z, Li Y, Du M, Huang G, Wang C, Chen X, Porembka MR, Lea J, Frankel AE, Fu YX, Chen ZJ, Gao J. A STING-activating nanovaccine for cancer immunotherapy. Nat Nanotechnol 2017;12:648-54. [PMID: 28436963 DOI: 10.1038/nnano.2017.52] [Cited by in Crossref: 312] [Cited by in F6Publishing: 414] [Article Influence: 62.4] [Reference Citation Analysis]
511 Stoll G, Ma Y, Yang H, Kepp O, Zitvogel L, Kroemer G. Pro-necrotic molecules impact local immunosurveillance in human breast cancer. Oncoimmunology 2017;6:e1299302. [PMID: 28507808 DOI: 10.1080/2162402X.2017.1299302] [Cited by in Crossref: 29] [Cited by in F6Publishing: 55] [Article Influence: 5.8] [Reference Citation Analysis]
512 Musella M, Manic G, De Maria R, Vitale I, Sistigu A. Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications. Oncoimmunology 2017;6:e1314424. [PMID: 28638743 DOI: 10.1080/2162402X.2017.1314424] [Cited by in Crossref: 49] [Cited by in F6Publishing: 66] [Article Influence: 9.8] [Reference Citation Analysis]
513 Mourik BC, Lubberts E, de Steenwinkel JEM, Ottenhoff THM, Leenen PJM. Interactions between Type 1 Interferons and the Th17 Response in Tuberculosis: Lessons Learned from Autoimmune Diseases. Front Immunol 2017;8:294. [PMID: 28424682 DOI: 10.3389/fimmu.2017.00294] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
514 Dallari S, Macal M, Loureiro ME, Jo Y, Swanson L, Hesser C, Ghosh P, Zuniga EI. Src family kinases Fyn and Lyn are constitutively activated and mediate plasmacytoid dendritic cell responses. Nat Commun 2017;8:14830. [PMID: 28368000 DOI: 10.1038/ncomms14830] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
515 Müller L, Aigner P, Stoiber D. Type I Interferons and Natural Killer Cell Regulation in Cancer. Front Immunol 2017;8:304. [PMID: 28408907 DOI: 10.3389/fimmu.2017.00304] [Cited by in Crossref: 50] [Cited by in F6Publishing: 68] [Article Influence: 10.0] [Reference Citation Analysis]
516 Wolff F, Leisch M, Greil R, Risch A, Pleyer L. The double-edged sword of (re)expression of genes by hypomethylating agents: from viral mimicry to exploitation as priming agents for targeted immune checkpoint modulation. Cell Commun Signal 2017;15:13. [PMID: 28359286 DOI: 10.1186/s12964-017-0168-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
517 Chen L, Liu S, Xu F, Kong Y, Wan L, Zhang Y, Zhang Z. Inhibition of Proteasome Activity Induces Aggregation of IFIT2 in the Centrosome and Enhances IFIT2-Induced Cell Apoptosis. Int J Biol Sci 2017;13:383-90. [PMID: 28367102 DOI: 10.7150/ijbs.17236] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
518 Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nat Commun 2017;8:14340. [PMID: 28194010 DOI: 10.1038/ncomms14340] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 15.0] [Reference Citation Analysis]
519 Suda K, Murakami I, Yu H, Kim J, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR. Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. J Thorac Oncol 2017;12:1015-20. [PMID: 28193529 DOI: 10.1016/j.jtho.2017.02.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
520 Veglia F, Gabrilovich DI. Dendritic cells in cancer: the role revisited. Curr Opin Immunol 2017;45:43-51. [PMID: 28192720 DOI: 10.1016/j.coi.2017.01.002] [Cited by in Crossref: 163] [Cited by in F6Publishing: 214] [Article Influence: 32.6] [Reference Citation Analysis]
521 Lu C, Talukder A, Savage NM, Singh N, Liu K. JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer. Oncoimmunology. 2017;6:e1291106. [PMID: 28405527 DOI: 10.1080/2162402x.2017.1291106] [Cited by in Crossref: 65] [Cited by in F6Publishing: 83] [Article Influence: 13.0] [Reference Citation Analysis]
522 Arimoto KI, Löchte S, Stoner SA, Burkart C, Zhang Y, Miyauchi S, Wilmes S, Fan JB, Heinisch JJ, Li Z, Yan M, Pellegrini S, Colland F, Piehler J, Zhang DE. STAT2 is an essential adaptor in USP18-mediated suppression of type I interferon signaling. Nat Struct Mol Biol 2017;24:279-89. [PMID: 28165510 DOI: 10.1038/nsmb.3378] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 15.2] [Reference Citation Analysis]
523 Zainulabadeen A, Yao P, Zare H. Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma. PLoS One 2017;12:e0170025. [PMID: 28114321 DOI: 10.1371/journal.pone.0170025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
524 Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clin Epigenetics 2017;9:4. [PMID: 28149332 DOI: 10.1186/s13148-017-0312-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
525 Nakamura K, Smyth MJ. Targeting cancer-related inflammation in the era of immunotherapy. Immunol Cell Biol 2017;95:325-32. [PMID: 27999432 DOI: 10.1038/icb.2016.126] [Cited by in Crossref: 76] [Cited by in F6Publishing: 95] [Article Influence: 15.2] [Reference Citation Analysis]
526 Aitken AS, Roy DG, Bourgeois-Daigneault MC. Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines 2017;5:E3. [PMID: 28536346 DOI: 10.3390/biomedicines5010003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
527 Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer 2016;4:90. [PMID: 28018601 DOI: 10.1186/s40425-016-0188-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
528 Gilboa E. A quantum leap in cancer vaccines? J Immunother Cancer 2016;4:87. [PMID: 28018600 DOI: 10.1186/s40425-016-0192-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
529 Galluzzi L, Kepp O, Chan FK, Kroemer G. Necroptosis: Mechanisms and Relevance to Disease. Annu Rev Pathol. 2017;12:103-130. [PMID: 27959630 DOI: 10.1146/annurev-pathol-052016-100247] [Cited by in Crossref: 209] [Cited by in F6Publishing: 267] [Article Influence: 34.8] [Reference Citation Analysis]
530 Apps JR, Martinez-barbera JP. Molecular pathology of adamantinomatous craniopharyngioma: review and opportunities for practice. FOC 2016;41:E4. [DOI: 10.3171/2016.8.focus16307] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
531 Venuta A, Wolfram J, Shen H, Ferrari M. Post-nano strategies for drug delivery: Multistage porous silicon microvectors. J Mater Chem B 2017;5:207-19. [PMID: 28670454 DOI: 10.1039/C6TB01978A] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
532 Achard C, Guillerme JB, Bruni D, Boisgerault N, Combredet C, Tangy F, Jouvenet N, Grégoire M, Fonteneau JF. Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells. Oncoimmunology 2017;6:e1261240. [PMID: 28197384 DOI: 10.1080/2162402X.2016.1261240] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
533 Hess J, Unger K, Orth M, Schötz U, Schüttrumpf L, Zangen V, Gimenez-Aznar I, Michna A, Schneider L, Stamp R, Selmansberger M, Braselmann H, Hieber L, Drexler GA, Kuger S, Klein D, Jendrossek V, Friedl AA, Belka C, Zitzelsberger H, Lauber K. Genomic amplification of Fanconi anemia complementation group A (FancA) in head and neck squamous cell carcinoma (HNSCC): Cellular mechanisms of radioresistance and clinical relevance. Cancer Lett 2017;386:87-99. [PMID: 27867017 DOI: 10.1016/j.canlet.2016.11.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
534 Wang Y, Nan J, Willard B, Wang X, Yang J, Stark GR. Negative regulation of type I IFN signaling by phosphorylation of STAT2 on T387. EMBO J 2017;36:202-12. [PMID: 27852626 DOI: 10.15252/embj.201694834] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
535 Bu Y, Liu F, Jia QA, Yu SN. Decreased Expression of TMEM173 Predicts Poor Prognosis in Patients with Hepatocellular Carcinoma. PLoS One 2016;11:e0165681. [PMID: 27814372 DOI: 10.1371/journal.pone.0165681] [Cited by in Crossref: 26] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
536 Shi WY, Cao C, Liu L. Interferon α Induces the Apoptosis of Cervical Cancer HeLa Cells by Activating both the Intrinsic Mitochondrial Pathway and Endoplasmic Reticulum Stress-Induced Pathway. Int J Mol Sci. 2016;17:pii E1832. [PMID: 27827850 DOI: 10.3390/ijms17111832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
537 Wang S, Campos J, Gallotta M, Gong M, Crain C, Naik E, Coffman RL, Guiducci C. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A 2016;113:E7240-9. [PMID: 27799536 DOI: 10.1073/pnas.1608555113] [Cited by in Crossref: 118] [Cited by in F6Publishing: 138] [Article Influence: 19.7] [Reference Citation Analysis]
538 Stanton SE, Disis ML. Clinical significance of tumor-infiltrating lymphocytes in breast cancer. J Immunother Cancer 2016;4:59. [PMID: 27777769 DOI: 10.1186/s40425-016-0165-6] [Cited by in Crossref: 198] [Cited by in F6Publishing: 280] [Article Influence: 33.0] [Reference Citation Analysis]
539 Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunogenic cell death in cancer and infectious disease. Nat Rev Immunol 2017;17:97-111. [PMID: 27748397 DOI: 10.1038/nri.2016.107] [Cited by in Crossref: 998] [Cited by in F6Publishing: 1186] [Article Influence: 166.3] [Reference Citation Analysis]
540 de Charette M, Marabelle A, Houot R. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy? Eur J Cancer 2016;68:134-47. [PMID: 27755997 DOI: 10.1016/j.ejca.2016.09.010] [Cited by in Crossref: 53] [Cited by in F6Publishing: 66] [Article Influence: 8.8] [Reference Citation Analysis]
541 Moriguchi T, Kaneumi S, Takeda S, Enomoto K, Mishra SK, Miki T, Koshimizu U, Kitamura H, Kondo T. Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling. Oncoimmunology 2016;5:e1242547. [PMID: 28123880 DOI: 10.1080/2162402X.2016.1242547] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
542 Tao J, Zhou X, Jiang Z. cGAS-cGAMP-STING: The three musketeers of cytosolic DNA sensing and signaling. IUBMB Life. 2016;68:858-870. [PMID: 27706894 DOI: 10.1002/iub.1566] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 9.3] [Reference Citation Analysis]
543 Rose R, Lamers SL, Nolan DJ, Maidji E, Faria NR, Pybus OG, Dollar JJ, Maruniak SA, McAvoy AC, Salemi M, Stoddart CA, Singer EJ, McGrath MS. HIV Maintains an Evolving and Dispersed Population in Multiple Tissues during Suppressive Combined Antiretroviral Therapy in Individuals with Cancer. J Virol 2016;90:8984-93. [PMID: 27466425 DOI: 10.1128/JVI.00684-16] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
544 Zhang KJ, Yin XF, Yang YQ, Li HL, Xu YN, Chen LY, Liu XJ, Yuan SJ, Fang XL, Xiao J, Wu S, Xu HN, Chu L, Katlinski KV, Katlinskaya YV, Guo RB, Wei GW, Wang DC, Liu XY, Fuchs SY. A Potent In Vivo Antitumor Efficacy of Novel Recombinant Type I Interferon. Clin Cancer Res 2017;23:2038-49. [PMID: 27683179 DOI: 10.1158/1078-0432.CCR-16-1386] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
545 Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol 2016;16:741-50. [PMID: 27667712 DOI: 10.1038/nri.2016.99] [Cited by in Crossref: 156] [Cited by in F6Publishing: 188] [Article Influence: 26.0] [Reference Citation Analysis]
546 Land WG, Agostinis P, Gasser S, Garg AD, Linkermann A. DAMP-Induced Allograft and Tumor Rejection: The Circle Is Closing. Am J Transplant 2016;16:3322-37. [PMID: 27529775 DOI: 10.1111/ajt.14012] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 8.2] [Reference Citation Analysis]
547 Lucarini V, Buccione C, Ziccheddu G, Peschiaroli F, Sestili P, Puglisi R, Mattia G, Zanetti C, Parolini I, Bracci L, Macchia I, Rossi A, D'Urso MT, Macchia D, Spada M, De Ninno A, Gerardino A, Mozetic P, Trombetta M, Rainer A, Businaro L, Schiavoni G, Mattei F. Combining Type I Interferons and 5-Aza-2'-Deoxycitidine to Improve Anti-Tumor Response against Melanoma. J Invest Dermatol 2017;137:159-69. [PMID: 27623509 DOI: 10.1016/j.jid.2016.08.024] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 5.8] [Reference Citation Analysis]
548 Meng J, Liu X, Zhang P, Li D, Xu S, Zhou Q, Guo M, Huai W, Chen X, Wang Q, Li N, Cao X. Rb selectively inhibits innate IFN-β production by enhancing deacetylation of IFN-β promoter through HDAC1 and HDAC8. Journal of Autoimmunity 2016;73:42-53. [DOI: 10.1016/j.jaut.2016.05.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
549 Zhang Y, Yang L, Wang H, Zhang G, Sun X. Respiratory syncytial virus non-structural protein 1 facilitates virus replication through miR-29a-mediated inhibition of interferon-α receptor. Biochem Biophys Res Commun 2016;478:1436-41. [PMID: 27569280 DOI: 10.1016/j.bbrc.2016.08.142] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
550 Villaverde MS, Targovnik AM, Miranda MV, Finocchiaro LME, Glikin GC. Cytotoxic effects induced by interferon-ω gene lipofection through ROS generation and mitochondrial membrane potential disruption in feline mammary carcinoma cells. Cytokine 2016;84:47-55. [DOI: 10.1016/j.cyto.2016.05.018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
551 Sullivan KD, Lewis HC, Hill AA, Pandey A, Jackson LP, Cabral JM, Smith KP, Liggett LA, Gomez EB, Galbraith MD, DeGregori J, Espinosa JM. Trisomy 21 consistently activates the interferon response. Elife 2016;5:e16220. [PMID: 27472900 DOI: 10.7554/eLife.16220] [Cited by in Crossref: 117] [Cited by in F6Publishing: 119] [Article Influence: 19.5] [Reference Citation Analysis]
552 Ottaviani G, Martinelli V, Rupel K, Caronni N, Naseem A, Zandonà L, Perinetti G, Gobbo M, Di Lenarda R, Bussani R, Benvenuti F, Giacca M, Biasotto M, Zacchigna S. Laser Therapy Inhibits Tumor Growth in Mice by Promoting Immune Surveillance and Vessel Normalization. EBioMedicine 2016;11:165-72. [PMID: 27475897 DOI: 10.1016/j.ebiom.2016.07.028] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
553 Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunotherapy plus radiation therapy for oncological indications. Oncoimmunology 2016;5:e1214790. [PMID: 27757313 DOI: 10.1080/2162402X.2016.1214790] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
554 Michelle Xu M, Pu Y, Weichselbaum RR, Fu YX. Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy. Oncogene 2017;36:585-92. [PMID: 27425593 DOI: 10.1038/onc.2016.231] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
555 Nuhn L, Vanparijs N, De Beuckelaer A, Lybaert L, Verstraete G, Deswarte K, Lienenklaus S, Shukla NM, Salyer AC, Lambrecht BN, Grooten J, David SA, De Koker S, De Geest BG. pH-degradable imidazoquinoline-ligated nanogels for lymph node-focused immune activation. Proc Natl Acad Sci U S A 2016;113:8098-103. [PMID: 27382168 DOI: 10.1073/pnas.1600816113] [Cited by in Crossref: 108] [Cited by in F6Publishing: 121] [Article Influence: 18.0] [Reference Citation Analysis]
556 Ma L, Wang H, Wu P, Hu J, Yin J, Wu S, Ge M, Sun W, Zhao J, Aisa HA, Li Y, Jiang J. Rupestonic acid derivative YZH-106 suppresses influenza virus replication by activation of heme oxygenase-1-mediated interferon response. Free Radical Biology and Medicine 2016;96:347-61. [DOI: 10.1016/j.freeradbiomed.2016.04.021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 33] [Article Influence: 4.0] [Reference Citation Analysis]
557 Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF. The host STING pathway at the interface of cancer and immunity. J Clin Invest 2016;126:2404-11. [PMID: 27367184 DOI: 10.1172/JCI86892] [Cited by in Crossref: 188] [Cited by in F6Publishing: 202] [Article Influence: 31.3] [Reference Citation Analysis]
558 Sang Y, Liu Q, Lee J, Ma W, McVey DS, Blecha F. Expansion of amphibian intronless interferons revises the paradigm for interferon evolution and functional diversity. Sci Rep 2016;6:29072. [PMID: 27356970 DOI: 10.1038/srep29072] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
559 Choi BY, Sim CK, Cho YS, Sohn M, Kim YJ, Lee MS, Suh SW. 2'-5' oligoadenylate synthetase-like 1 (OASL1) deficiency suppresses central nervous system damage in a murine MOG-induced multiple sclerosis model. Neurosci Lett 2016;628:78-84. [PMID: 27297771 DOI: 10.1016/j.neulet.2016.06.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
560 Hope C, Foulcer S, Jagodinsky J, Chen SX, Jensen JL, Patel S, Leith C, Maroulakou I, Callander N, Miyamoto S, Hematti P, Apte SS, Asimakopoulos F. Immunoregulatory roles of versican proteolysis in the myeloma microenvironment. Blood 2016;128:680-5. [PMID: 27259980 DOI: 10.1182/blood-2016-03-705780] [Cited by in Crossref: 70] [Cited by in F6Publishing: 77] [Article Influence: 11.7] [Reference Citation Analysis]
561 Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, Meng M, Fritz D, Vascotto F, Hefesha H, Grunwitz C, Vormehr M, Hüsemann Y, Selmi A, Kuhn AN, Buck J, Derhovanessian E, Rae R, Attig S, Diekmann J, Jabulowsky RA, Heesch S, Hassel J, Langguth P, Grabbe S, Huber C, Türeci Ö, Sahin U. Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy. Nature 2016;534:396-401. [PMID: 27281205 DOI: 10.1038/nature18300] [Cited by in Crossref: 652] [Cited by in F6Publishing: 782] [Article Influence: 108.7] [Reference Citation Analysis]
562 Budczies J, Bockmayr M, Denkert C, Klauschen F, Gröschel S, Darb-Esfahani S, Pfarr N, Leichsenring J, Onozato ML, Lennerz JK, Dietel M, Fröhling S, Schirmacher P, Iafrate AJ, Weichert W, Stenzinger A. Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival. Genes Chromosomes Cancer 2016;55:626-39. [PMID: 27106868 DOI: 10.1002/gcc.22365] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 9.0] [Reference Citation Analysis]
563 Fend L, Rusakiewicz S, Adam J, Bastien B, Caignard A, Messaoudene M, Iribarren C, Cremer I, Marabelle A, Borg C, Semeraro M, Barraud L, Limacher JM, Eggermont A, Kroemer G, Zitvogel L. Prognostic impact of the expression of NCR1 and NCR3 NK cell receptors and PD-L1 on advanced non-small cell lung cancer. Oncoimmunology 2017;6:e1163456. [PMID: 28197362 DOI: 10.1080/2162402X.2016.1163456] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
564 Saadeh D, Kurban M, Abbas O. Plasmacytoid dendritic cell role in cutaneous malignancies. J Dermatol Sci 2016;83:3-9. [PMID: 27236509 DOI: 10.1016/j.jdermsci.2016.05.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
565 Shukla S, Steinmetz NF. Emerging nanotechnologies for cancer immunotherapy. Exp Biol Med (Maywood) 2016;241:1116-26. [PMID: 27190253 DOI: 10.1177/1535370216647123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
566 Sun W, Ji W, Hu Q, Yu J, Wang C, Qian C, Hochu G, Gu Z. Transformable DNA nanocarriers for plasma membrane targeted delivery of cytokine. Biomaterials 2016;96:1-10. [PMID: 27131597 DOI: 10.1016/j.biomaterials.2016.04.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
567 Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents. Cancer Cell. 2015;28:690-714. [PMID: 26678337 DOI: 10.1016/j.ccell.2015.10.012] [Cited by in Crossref: 701] [Cited by in F6Publishing: 786] [Article Influence: 116.8] [Reference Citation Analysis]
568 Saleiro D, Kosciuczuk EM, Platanias LC. Beyond autophagy: New roles for ULK1 in immune signaling and interferon responses. Cytokine Growth Factor Rev 2016;29:17-22. [PMID: 27068414 DOI: 10.1016/j.cytogfr.2016.03.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
569 Sim CK, Cho YS, Kim BS, Baek IJ, Kim YJ, Lee MS. 2'-5' Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons. Cancer Immunol Immunother 2016;65:663-75. [PMID: 27034232 DOI: 10.1007/s00262-016-1830-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
570 Galdiero MR, Varricchi G, Marone G. The immune network in thyroid cancer. Oncoimmunology 2016;5:e1168556. [PMID: 27471646 DOI: 10.1080/2162402X.2016.1168556] [Cited by in Crossref: 49] [Cited by in F6Publishing: 59] [Article Influence: 8.2] [Reference Citation Analysis]
571 Katlinskaya YV, Katlinski KV, Yu Q, Ortiz A, Beiting DP, Brice A, Davar D, Sanders C, Kirkwood JM, Rui H, Xu X, Koumenis C, Diehl JA, Fuchs SY. Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression. Cell Rep 2016;15:171-80. [PMID: 27052162 DOI: 10.1016/j.celrep.2016.03.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 59] [Article Influence: 9.3] [Reference Citation Analysis]
572 Temizoz B, Kuroda E, Ishii KJ. Vaccine adjuvants as potential cancer immunotherapeutics. Int Immunol 2016;28:329-38. [PMID: 27006304 DOI: 10.1093/intimm/dxw015] [Cited by in Crossref: 126] [Cited by in F6Publishing: 138] [Article Influence: 21.0] [Reference Citation Analysis]
573 Klepsch V, Hermann-Kleiter N, Baier G. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy. Immunol Lett 2016;178:31-6. [PMID: 26992368 DOI: 10.1016/j.imlet.2016.03.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
574 Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology 2016;5:e1149674. [PMID: 27471617 DOI: 10.1080/2162402X.2016.1149674] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 6.8] [Reference Citation Analysis]
575 Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, Zitvogel L, Kepp O, Kroemer G. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology 2016;5:e1149673. [PMID: 27471616 DOI: 10.1080/2162402X.2016.1149673] [Cited by in Crossref: 84] [Cited by in F6Publishing: 91] [Article Influence: 14.0] [Reference Citation Analysis]
576 Galluzzi L, López-soto A, Kumar S, Kroemer G. Caspases Connect Cell-Death Signaling to Organismal Homeostasis. Immunity 2016;44:221-31. [DOI: 10.1016/j.immuni.2016.01.020] [Cited by in Crossref: 173] [Cited by in F6Publishing: 177] [Article Influence: 28.8] [Reference Citation Analysis]
577 Zitvogel L, Kroemer G. Subversion of anticancer immunosurveillance by radiotherapy. Nat Immunol 2015;16:1005-7. [PMID: 26343538 DOI: 10.1038/ni.3236] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
578 Kroemer G, Galluzzi L, Zitvogel L. STAT3 inhibition for cancer therapy: Cell-autonomous effects only? Oncoimmunology 2016;5:e1126063. [PMID: 27467938 DOI: 10.1080/2162402X.2015.1126063] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
579 Yu D, Zhao M, Dong L, Zhao L, Zou M, Sun H, Zhang M, Liu H, Zou Z. Design and evaluation of novel interferon lambda analogs with enhanced antiviral activity and improved drug attributes. Drug Des Devel Ther 2016;10:163-82. [PMID: 26792983 DOI: 10.2147/DDDT.S91455] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
580 Pol J, Buqué A, Aranda F, Bloy N, Cremer I, Eggermont A, Erbs P, Fucikova J, Galon J, Limacher JM, Preville X, Sautès-Fridman C, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Oncolytic viruses and cancer therapy. Oncoimmunology 2016;5:e1117740. [PMID: 27057469 DOI: 10.1080/2162402X.2015.1117740] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 9.9] [Reference Citation Analysis]
581 Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology 2016;5:e1115641. [PMID: 26942095 DOI: 10.1080/2162402X.2015.1115641] [Cited by in Crossref: 149] [Cited by in F6Publishing: 161] [Article Influence: 21.3] [Reference Citation Analysis]
582 Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology 2016;5:e1115942. [PMID: 27057468 DOI: 10.1080/2162402X.2015.1115942] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
583 Routy JP, Mehraj V, Cao W. HIV immunotherapy comes of age: implications for prevention, treatment and cure. Expert Rev Clin Immunol 2016;12:91-4. [PMID: 26629806 DOI: 10.1586/1744666X.2016.1112269] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
584 Regan D, Dow S. Manipulation of Innate Immunity for Cancer Therapy in Dogs. Vet Sci 2015;2:423-39. [PMID: 29061951 DOI: 10.3390/vetsci2040423] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
585 El-baky NA, Uversky VN, Redwan EM. Human consensus interferons: Bridging the natural and artificial cytokines with intrinsic disorder. Cytokine & Growth Factor Reviews 2015;26:637-45. [DOI: 10.1016/j.cytogfr.2015.07.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
586 Leitner NR, Witalisz-Siepracka A, Strobl B, Müller M. Tyrosine kinase 2 - Surveillant of tumours and bona fide oncogene. Cytokine 2017;89:209-18. [PMID: 26631911 DOI: 10.1016/j.cyto.2015.10.015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
587 Smyth MJ, Ngiow SF, Ribas A, Teng MW. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2016;13:143-158. [PMID: 26598942 DOI: 10.1038/nrclinonc.2015.209] [Cited by in Crossref: 463] [Cited by in F6Publishing: 523] [Article Influence: 66.1] [Reference Citation Analysis]
588 Isorce N, Lucifora J, Zoulim F, Durantel D. Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies. Antiviral Res. 2015;122:69-81. [PMID: 26275801 DOI: 10.1016/j.antiviral.2015.08.008] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
589 Fucikova J, Moserova I, Urbanova L, Bezu L, Kepp O, Cremer I, Salek C, Strnad P, Kroemer G, Galluzzi L, Spisek R. Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. Front Immunol 2015;6:402. [PMID: 26300886 DOI: 10.3389/fimmu.2015.00402] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 10.7] [Reference Citation Analysis]
590 [DOI: 10.1101/503086] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
591 [DOI: 10.1101/2020.07.13.200477] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
592 [DOI: 10.1101/2020.08.25.267336] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Reference Citation Analysis]